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Abstract 
 
    Astrovirus and Norovirus Infection In A Paediatric Setting 
 
Introduction 
Astrovirus and norovirus are both agents that play an important causal role in gastroenteritis 
infections in children worldwide. Astroviruses are mainly found in children under five years 
of age and are responsible for sporadic outbreaks of gastroenteritis. Noroviruses are found 
across all age groups and can cause large outbreaks in the community and institutions such as 
hospitals and schools. Transmission for both viruses is usually by the faecal-oral route 
through contaminated food, water and also by aerosols and fomites.  Infections occur all year 
round, with a winter peak in temperate areas. Astrovirus and norovirus are RNA viruses with 
positive-sense, single-strand genomes. Human astrovirus has eight genotypes, HAstV-1 to 
HAstV-8, with HAstV-1 the most common. Norovirus is divided into five genogroups,    
NoV GI to GV, with human norovirus in genogroups GI, GII and GIV. The most common 
genotype worldwide is NoV GII.4.   
Aim 
The aim of this research project was to study the role of astrovirus and norovirus in children 
with diarrheal symptoms at The Children’s Hospital at Westmead (CHW) post rotavirus 
vaccine introduction.   In Australia, the role that these viruses play in children presenting to 
paediatric hospitals has not been examined since rotavirus vaccination was included in the 
national immunisation program in 2007. We wanted to assess whether the activity of these 
two viruses had increased with the decrease in rotavirus activity. From our two year study we 
hoped to determine the prevalence and nature of infection by analysis of viral infection rates, 
vii 
 
seasonal distributions, age distributions, patient types infected, nosocomial infections, viral 
genotypes and performance of phylogenetic analysis. To enhance our analysis, we aimed to 
develop RT-PCR based assays to be used in conjunction with ELISA methods for specimen 
testing. From our study we hoped to determine the most suitable tests for routine diagnostic 
use. 
Method                                                                                                                                        
Stool specimens from children presenting with diarrheal symptoms to the Emergency 
Department, Outpatient Departments and from inpatients were collected over a two year 
period from January, 2009 to December, 2010. These specimens were tested for astrovirus 
and norovirus antigens using commercial ELISA kits. Nested Reverse Transcription–
Polymerase Chain Reaction assays (nRT-PCR) were developed for both viruses to detect 
viral RNA. Positive ELISA specimens were tested in the nRT-PCR assays and specific 
products were sequenced. Sequence results were used to determine viral genotypes and 
perform phylogenetic analysis. To compare the performance of the commercial ELISA tests 
to the in-house developed nRT-PCR assays, negative ELISA specimens were randomly 
selected and tested in the nRT-PCR assays.  
Results                                                                                                                                       
In the two year study period, over 5,000 specimens were tested for astrovirus and norovirus 
by the ELISA method. The ELISA methods showed an incidence of 0.5% and 6.6% for 
astrovirus and norovirus, respectively. Compared to the nRT-PCR assays, the astrovirus 
ELISA had a sensitivity of 77.4% (95% CI= 58.9-90.4%) and specificity of 100% (95% 
CI=97.5-100.0%) and the norovirus sensitivity was 93.3% (95% CI= 90.2-95.75) with a 
specificity of 94.2% (95% CI= 85.8-98.4%). The estimated incidences if all study specimens 
were tested by both ELISA and nRT-PCR were 5.1% (95% CI= 4.53-5.77%) for astrovirus 
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and 30.9% (95% CI= 29.63-32.19%) for norovirus. Infection rates were similar in 2009 and 
2010, and highest in children under two years of age. Astrovirus infection was mainly in 
Emergency patients and immunocompromised patients. The majority of norovirus infections 
were in Emergency patients and there were a large number of nosocomial infections. 
Astovirus genotypes HAstV-1 to 4 were detected with HAstV-1a the predominant genotype. 
There were 12 norovirus genotypes detected: NoV GI.1, GI.2, GI.4, GI.6, GI.13, GII.2, GII.3, 
GII.4, GII.6, GII.7, GII.12, GII.13 with GII.4 the predominant genotype. In 2009, the 
epidemic GII.4 2008 variant was dominant and this was replaced by the pandemic GII.4 New 
Orleans variant in 2010. 
Conclusion                                                                                                             
Astrovirus was an uncommon cause of diarrheal illness in children presenting to the 
Children’s Hospital at Westmead. Taking this into consideration with the lower sensitivity of 
the ELISA test, the nRT-PCR assay would be more suitable for testing stool specimens. In 
contrast, norovirus was a common cause of diarrheal illness and the norovirus ELISA test 
with its high sensitivity would be a rapid, easy and relatively inexpensive method to routinely 
test specimens. The impact of the rotavirus vaccination program is difficult to assess from 
this two year study period as although astrovirus activity was low, norovirus activity was 
high due to the pandemic GII.4 New Orleans variant. Further studies will be required, both in 
Australia and worldwide, to assess the effect of the rotavirus vaccines on astrovirus and 
norovirus infection. 
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     1.1   ASTROVIRUS AND NOROVIRUS 
Human astrovirus was first identified in 1975 by electron microscopy examination of faecal 
samples from an outbreak of gastroenteritis in babies at a maternity unit in England (1). The 
virus was described as particles of 29-30nm in diameter, differing in size and morphology 
from Rotavirus and Norwalk agent. The name “astrovirus” (astron= star in Greek) was given 
a few months later, when these particles were again observed by electron microscopy of 
faecal samples from children with diarrhoea (2). Astroviruses were described as small 
particles with a star-like morphology and named after this characteristic feature. Human 
astroviruses are classified in the Astroviridae family.                                                  
Norovirus was first identified as a result of an outbreak of gastroenteritis in school children 
and their teachers in Norwalk, Ohio, U.S. in 1968 (3).  In 1972, using infected stool filtrates 
from this outbreak, a 27nm particle was identified by electron microscopy (4). The virus was 
known as Norwalk virus/agent until 1990, when it was classified in the  Caliciviridae family 
and named “Norovirus” (5). The name calicivirus (calyx = cup in Latin) describes the cup-
like depressions seen on the virus surface when viewed by electron microscopy (EM).              
Astrovirus and norovirus are both RNA viruses that play an important causal role in 
gastroenteritis worldwide. The development of more sensitive detection methods such as 
ELISA (Enzyme-linked Immunosorbent Assay) and Reverse Transcription-Polymerase Chain 
Reaction (RT-PCR) has increased the detection rates for both viruses. The incidence rates in 
hospitalised children have been reported as between 1.5-28.2% (6-8) for astrovirus infection, 
and 5.9-25.9% (9-11) for norovirus infection.                                                                                                                 
Astrovirus infection is mainly found in young children under five years of age, but can also 
infect the elderly and immunocompromised patients. It is responsible for sporadic outbreaks 
in the community and outbreaks in institutions such as hospitals, nursing homes and day care 
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centres. Norovirus infection is found across all age groups and can cause large outbreaks in 
institutions such as schools and hospitals, cruise ships and restaurants. Infection with these 
two viruses occurs all year round, with peak incidences in the Winter months in temperate 
regions (12). 
 
1.2  CLASSIFICATION 
1.2.1   ASTROVIRUS CLASSIFICATION                                                   
The Astroviridae family is divided into two genera: Mamastrovirus and Avastrovirus, based 
on whether they infect mammals or birds. The Mamastrovirus genera are astroviruses that 
have been found in mammals: humans, lambs, calves, deer, piglets, kittens, mice, dogs and 
mink whilst the Avastrovirus are astroviruses that have been  found  in birds: chickens, duck 
and guinea fowls (12). 
1.2.1.1   Human Astrovirus genotypes                                                                
There are eight known genotypes/serotypes of human astrovirus: HAstV-1 to HAstV-8. They 
are grouped into genogroup A (HAstV-1 to 5, and HAstV-8) and genogroup B (HAstV-6 and 
7). HAstV-1 is the most frequently detected genotype worldwide (6, 13). The incidence of 
HAstV-2 to 4 infection is less common, but has been detected in many studies (6, 14-17). 
The incidence of HAstV-5 to 8 is uncommon (17, 18). In recent years, two other groups of 
human astroviruses have been identified: AstV-MLB and HMOAstV (19-21). They are both 
highly divergent from the eight classic genotypes and further studies are needed to determine 
their role in clinical disease.    
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1.2.2   NOROVIRUS CLASSIFICATION                                                            
The Caliciviridae family is divided into four genera: Norovirus, Sapovirus, Vesivirus and 
Lagovirus. There may be a fifth genus: Becovirus (22). Norovirus and Sapovirus are 
caliciviruses that have been found in humans and a few animals. Vesivirus and Lagovirus 
contain only animal strains. Vesivirus has been found in pigs, cats, and sea lions.                       
Lagovirus has been found in rabbits and hares. Becovirus may represent the bovine 
caliciviruses known as Newbury 2 and Jena virus (23). 
1.2.2.1   Human Norovirus genotypes                                                             
The Norovirus genus is divided into several genogroups and genotypes. There are five 
genogroups: GI to GV. Genogroups GI, II and IV contain the human noroviruses. GIII 
contains the bovine and ovine strains and GV the murine strains.  There are over 29 different 
norovirus genotypes within the five genogroups (24). To date; GI has 8 genotypes, GII has 
17, GIII and GIV have 2, and GV has 1 (25). Genogroups I and II are responsible for the 
majority of outbreaks worldwide. Recent studies have shown a predominance of GII strains, 
with GII.4 emerging as the principal genotype (26, 27).  
 
  1.3  VIRAL STRUCTURE 
1.3.1 ASTROVIRUS MORPHOLOGY                                                     
Astroviruses are 27-30 nm in diameter, are nonenveloped and have a single stranded  
positive-sense RNA genome. They have icosahedral morphology and a characteristic starlike 
surface structure when viewed by EM (Figure 1.1).  The capsid shell is solid, rippled and has 
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dimeric spikes that extend 5nm from the surface. These spikes create the five to six pointed 
star appearance.          
                                                                                                                                                                                                                                                                                                                                                                                                      
Figure 1.   A: Electron micrograph of HAstV in a faecal specimen showing typical star appearance  
B: 3-D view of cell culture-adapted HAstV- 1 (Oxford strain) imaged by cryoelectron microscopy 
showing the dimeric spikes. This figure adapted from Mendez and Arias, 2007 (28)   
 
 
1.3.1.1   Astrovirus genome                                                                                
The astrovirus genome varies between 6.8 kb to 7.3 kb in size depending on the species of 
origin: Human astrovirus (HAstV) is approximately 6.8 kb. The astrovirus genome has three 
identified open reading frames (ORFs): ORF1a, ORF1b and ORF2. The first two encode the 
non-structural proteins at the 5’ end of the genome, and ORF2 encodes the structural proteins 
at the 3’ end. ORF1a encodes the viral protease: serine protease and ORF1b the RNA-
dependant RNA  polymerase, and they are both linked by a ribosomal frameshifting motif 
which translates into the RNA-dependant RNA polymerase (29).               
1.3.1.2   Astrovirus genome replication                                                                                     
During infection, two positive-sense viral RNAs are produced:  full length genomic RNA 
(gRNA, 6.8kb) and subgenomic RNA (sgRNA, 2.4kb), (Figure 1.2). The sgRNA directs the 
synthesis of the structural 90k-Da polyprotein VP90. The gRNA serves as a template for the 
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synthesis of the non-structural proteins: nsp 1 a and nsp 1 ab. nsp 1 ab is produced by a 
translational frameshift mechanism using the frameshift signal (fs). Both nsp 1 a and nsp 1 ab 
are involved in the synthesis of the three viral RNAs: gRNA, sgRNA and negative-sense 
RNA. gRNA and sgRNA are produced from a negative-sense full-length antigenomic RNA. 
The negative-sense RNA is used as a template to produce more gRNA and sgRNA. The 
synthesis of sgRNA may require an internal sequence in the negative-sense full-length RNA 
to act as a promoter for the viral transcriptase, although the identity of this sequence has not 
been defined (28). Walter et al. 2001 (30) suggested that 120 nucleotides upstream of ORF2 
may be part of the promoter for sgRNA synthesis.  
        
 
Figure 1.2  HAstV genome replication – numbers in the squares represent the hypothetical order of 
the genome replication steps. This figure adapted from Mendez and Arias, 2009 (12) 
 
 
Assembled virus particles containing VP90 are processed by intracellular proteases called 
capases, to yield particles of various sizes, depending on such factors as the virus genotype or 
virus source. For genotype 8, a particle sized 70kD (VP70) is formed and released from the 
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cell (Figure 1.3). These VP70 virions are partially infectious. Complete activation requires 
these particles to be cleaved by trypsin at specific sites to yield fully infectious virus particles 
containing three proteins VP34, VP27 and VP25 (28). The common feature of astroviruses is 
that fully infectious particles are formed by three proteins in the range of 32-34, 27-29 and 
25-26 kD.   
                                                                 
      Figure 1.3  Scheme of astrovirus and the structural proteins of a fully infectious HAstV- 
      8 strain. This figure adapted from Mendez and Arias, 2009 (12) 
       
 
1.3.2 NOROVIRUS MORPHOLOGY                                                      
Caliciviruses are 30-38 nm in diameter, are nonenveloped, and have a single stranded 
positive-sense RNA genome. They have icosahedral symmetry and characteristic cup-like 
depressions on their surface when viewed under the electron microscope (Figure 1.4). 
Norovirus has a smoother surface structure than other caliciviruses such as sapoviruses, with 
norovirus cup-like depressions being less pronounced. The Norovirus capsid protein is folded 
into 90 dimers that give a shell domain with arch-like capsomers protruding. These arches are 
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arranged in a way that there are large hollows which appear as the characteristic cup-like 
structures (25).                         
                      
Figure 1.4  A  Electron micrograph of norovirus in a human faecal specimen showing the  
cup-like feature. Bar = 50nm B: 3-D view of norovirus showing the 90 dimeric arches. This figure 
adapted from Atmar and Estes, 2006 (26) 
 
1.3.2.1.   Norovirus genome                                                                                                   
The norovirus genome is approximately 7.5 to 7.7 kb in size and has 4 open reading frames 
(ORFs): ORF1, ORF2, ORF3 and ORF4. ORF1 encodes the non-structural proteins, ORF2 
the capsid protein, and ORF3 a minor structural protein (Figure 1.5). ORF1 encodes a large 
polyprotein that is cleaved after synthesis into the non-structural proteins NS1 to NS7. These 
are important for replicating the virus but not found in virus particles. ORF2 encodes the 
major viral capsid protein, VP1. This capsid protein can self assemble into virus-like particles 
(VLPs).  ORF3 encodes a minor capsid protein, VP2. The role of VP2 is still unknown, 
although it may be involved in the nucleic acid binding and encapsidation of the viral RNA 
(31). ORF4 is a recently identified protein and is thought to function as a virulence factor by 
aiding immune evasion (32). 
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Figure 1.5   Genomic structure and organisation of norovirus.                         
                     This figure adapted from Hyde and Mackenzie, 2012 (33) 
 
1. 3.2.2.  Norovirus genome replication                                                                                  
The mechanism by which norovirus enters the host cell and its replication strategies are not 
completely understood as norovirus has not been able to be grown in cell culture. However, 
there has been some recent success with growing a murine norovirus, MNV-1, in primary 
dendritic cells and macrophages (34). Also, the human norovirus genotype GII.3 has been 
cloned and expressed in human embryonic kidney cells using a T7 vaccinia virus expression 
system (35). From the infection information we have to date, the positive-sense virus gRNA 
serves as an mRNA template and is translated by the host cell into a single polypeptide from 
which the non-structural proteins NS1 to NS7 are produced. The viral polypeptide is co- and 
post- transitionally cleaved by the viral protease NS6, releasing functional polyprotein 
species and mature viral proteins to facilitate further rounds of replication. After translation 
and proteolytic release of viral proteins, the positive-sense genome functions as a template for 
negative-strand RNA synthesis. Replication is mediated by viral RNA-dependant RNA 
polymerase (NS7). Negative-sense RNA transcripts are then used as a template for synthesis 
of more full-length genomic RNA (gRNA) as well as positive-sense subgenomic RNA 
(sgRNA). The sgRNA containing ORF2 and ORF3 serves as a template for production of the 
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structural proteins, VP1 and VP2 respectively (25). After further replication rounds, full-
length gRNA are packaged into virions. However, it is not known how these virions are 
released from infected cells.  
 
1.4.   EPIDEMOLOGY 
1.4.1   ASTROVIRUS  
1.4.1.1   Astrovirus incidence and prevalence                                           
Astroviruses are a common cause of gastroenteritis infections worldwide, mainly found in the 
paediatric population. They are found throughout the year, with a peak incidence during the 
colder winter months in temperate areas. In tropical areas they peak during the rainy season 
(12). They are responsible for sporadic infections, with children under five years of age being 
the largest group effected.  The incidence of astrovirus infection ranges from 1 to 9% in 
children from developing and developed countries (7, 36-38). Some studies have reported 
that in certain areas within developing countries, such as Mexico and Chile, the incidence is 
as high as 16-28% (6, 39-41). In these areas, astrovirus is second to rotavirus as the most 
common cause of gastroenteritis. Outbreaks amongst young children usually occur in 
institutions such as child-care centres, schools, hospitals and also communities (37, 42, 43). 
Astrovirus has also been recognised as an important cause of infection amongst the elderly.  
HAstV-1 has been the reported to be the main genotype responsible for 12-55% of astrovirus 
outbreaks in aged-care facilities (44). Astrovirus has been reported as an important cause of 
diarrhoea in immunocompromised patients (45, 46). HAstV-3 has been found in HIV 
patients, and HAstV-1 in bone marrow transplant patients. They have been isolated in 
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outbreaks in adults, in military recruits with  HAstV-3 (47), and a large food-borne outbreak 
in Japan (genotype not determined) infecting thousands of school children and their teachers 
(48). Of the eight known genotypes of HAstV, the most common strain worldwide appears to 
be HAstV-1. Some studies have detected high levels of HAstV-2, HAstV-3 and HAstV-4  
(15, 16, 30, 48). HAstV-5 to HAstV-8 are the least common genotypes.  
1.4.1.2   Astrovirus transmission                                                                   
Astrovirus infection usually results from contaminated food or water. One of the largest 
outbreaks occurred in Japanese school children and their teachers from a contaminated 
foodsource in 1991 (48). As with most viruses causing gastroenteritis, transmission is also by 
the faecal-oral route and by fomites. HAstV can survive for long periods of time on surfaces 
and this may be a major route for nosocomial infections. It is important for those handling 
food to follow hygienic procedures and water chlorination can diminish astrovirus activity. 
Although astrovirus is resistant to many detergents; a combination of detergent and sodium 
hypochlorite will diminish virus activity on surfaces and decrease nosocomial infections (49). 
 
1.4.2   NOROVIRUS                                                                                                           
1.4.2.1   Norovirus incidence and prevalence                                                         
Noroviruses have been recognised as the most important causative agent of epidemic 
gastroenteritis for all age groups in both developing and developed countries (Table 1.1). 
They are found throughout the year, with a peak in incidence during the colder winter 
months.  They are responsible for more than half of all gastroenteritis outbreaks worldwide, 
and have been identified in 73-95% of epidemic nonbacterial gastroenteritis (26). Outbreaks 
have occurred in camps, schools, cruise ships, military ships, restaurants, nursing homes and 
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hospitals. The source of infection is usually contaminated drinking water, swimming water, 
and poorly cooked or uncooked food. Noroviruses are also responsible for sporadic 
gastroenteritis in the community; with infected persons presenting to their private doctors, 
hospital outpatient clinics and emergency units (36, 37, 50, 51). Asymptomatic infections can 
occur and these people may be the source of sporadic infection. Nosocomial infections are a 
problem in specific populations, such as inpatients in hospitals and aged-care facilities, with 
increased duration of stay and increased mortality. Hospital wards may need to be closed to 
ensure proper disinfection of contaminated areas (52, 53). Immunocompromised patients, 
such as transplant patients, are particularily susceptible to nosocomial infection. They may 
develop chronic diarrhoea and shed virus for months. Hospital wards with these patients must 
have a high standard of infection control to prevent norovirus contamination (45). Norovirus 
infection is a common cause of traveller’s diarrhoea, particularly on cruise ships. Infection 
rates can be as high as 30% and continue over several voyages, causing persistent infection 
even after decontamination (54, 55). Most norovirus infections are caused by G I and G II 
strains. Recent studies have shown a predominance of GII, with GII.4 emerging as the main 
genotype for worldwide infection (26). Most infections involve one strain of norovirus, but 
co-infections can occur if the source of infection is from contaminated water or shellfish (56) 
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Table 1.1  Frequency of Norovirus infections and genotypes in outbreaks of acute 
gastroenteritis. This table adapted from Atmar and Estes, 2006 (26)          
 
 
                                               
 
1.4.2.2   Norovirus transmission                                                                                           
Norovirus is transmitted by the faecal-oral route through faecal contamination of food, water, 
person-to-person spread, fomites and airborne droplets from vomitus. It is estimated that the 
infective dose for norovirus is less than 100 virus particles (57). Droplet transmission of 
norovirus occuring through vomitus has been reported due to of infected persons vomiting in 
emergency rooms and restaurants (58, 59). Norovirus fomites survive on surfaces, and this 
leads to secondary infections especially on cruise ships and in hospitals. Norovirus is resistant 
to many disinfectants, and it is recommended to use the combination of detergent followed by 
sodium hypochlorite for complete surface decontamination (49). 
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   1.5.  CLINICAL FEATURES 
1.5.1   ASTROVIRUS 
1.5.1.1.  Astrovirus incubation period                                                                    
The incubation period of astrovirus infection is one to three days after exposure, and the 
illness usually lasts from four to five days. Clinical symptoms include diarrhoea, vomiting, 
fever, anorexia, abdominal pain and mild dehydration. The watery diarrhoea lasts for two to 
three days and symptoms are usually not severe enough to require hospitalisation. Death from 
astrovirus infection is extremely rare. Viral particles can be present in faeces for up to two 
weeks after symptoms disappear. Viral shedding can be much longer in immunodeficient 
patients with chronic infection (46). There have been reports of severe gastroenteritis from 
infections with genotype 3 and genotype 6, although this may be due to particular infecting 
strains rather than the whole genotype (46, 60, 61).  
1.5.1.2   Astrovirus pathogenesis                                                                                    
Intestinal epithelium cells are the primary site of astrovirus replication in humans. 
Histological studies with infected mammal tissues, which are probably similar to human 
infections, show that the virus is localised in the epithelial as well as subepithelial 
macrophages of the small intestine (28). From biopsy samples of an immunodeficient patient, 
infection appears to be mainly in the jejunum and to a lesser extent the duodenum (Figure 
1.6).  Inflammation does not seem to be central to illness pathogenesis (62). 
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Figure 1.6   A – Photomicrograph of a jejuna biopsy specimen from a bone marrow transplant 
recipient with astrovirus infection showing villus blunting, nonspecific alterations in surface epithelial 
cells, and a mixed lamina propria inflammatory infiltrate (X100)  C - Same biopsy sample 
immunostained with anti-astrovirus antibody and showing extensive staining of surface epithelial 
cells, most commonly near the villus tips (X100).  This figure adapted from Sebire et al., 2004 (62)  
   
1.5.1.3   Astrovirus treatment                                                                   
Gastroenteritis caused by astrovirus is not as severe as that experienced with viruses such as 
norovirus and rotavirus, and specific treatment is seldomly required. Infected persons usually 
only require oral rehydration.  No antiviral agents against astrovirus are available and this can 
be a problem in immunosuppressed patients with persistent, chronic infection.   
 
1.5.2   NOROVIRUS                                                                                         
1.5.2.1   Norovirus incubation period                                                             
The incubation period of norovirus infection is one to two days after exposure, and the illness 
usually lasts for one to four days. Clinical symptoms include sudden onset of vomiting, 
diarrhoea, fever, nausea, mild dehydration and abdominal pain. The watery diarrhoea does 
not contain blood. With norovirus infection, symptoms vary from person to person. The 
illness is usually self limiting and does not require hospitalisation. Deaths from norovirus 
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have occurred due to inhalation of vomitus or severe dehydration in patients with an 
underlying medical conditions.Viral shedding can occur for up to two weeks after symptoms 
disappear. Immunocompromised patients may develop chronic diarrhoea and shed virus for 
months to years. 
1.5.2.2   Norovirus pathogenesis                                                                                           
The primary site of norovirus replication in humans has not yet been determined, but it is 
assumed to be in the upper intestinal tract.  Proximal intestinal biopsies from adult volunteers 
infected with norovirus have shown broadening and blunting of intestinal villi, crypt cell 
hyperplasia, cytoplasmic vacuolization, infiltration of polymorphonuclear and mononuclear 
cells into the lamina propria, but the mucosa itself remained intact (Figure 1.7) (63). Virus 
has not been detected by EM in the epithelial cells of the mucosa. Nausea and vomiting 
associated with norovirus infection may be due to abnormal gastric motor function, however,  
the precise mechanism is not known (64). 
        Figure 1.7   A – Jejunal biopsy from an uninfected human volunteer. B -  jejunal   
         biopsy from the same volunteer after infection with norovirus,showing broadening and     
         flattening of the villi.This figure adapted from Atmar and Estes, 2009 (25) 
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1.5.2.3   Norovirus treatment                                                                    
Gastroenteritis from norovirus does not normally require treatment, except for oral 
rehydration. Hospitalisation may be required for young children and the elderly with 
intravenous fluids administration.  Adults do not normally require hospitalisation. There are 
no antiviral agents available to treat norovirus infection. 
 
1.6   DIAGNOSTIC VIROLOGY 
1.6.1   CELL CULTURE                                                                             
Human astrovirus (HAstV-1 strain) was first cultured from faeces using a continuous human 
colon adenocarcinoma cell line (Caco-2 cells) and trypsin treatment of the sample (65). Other 
cell lines such as T-84 (adenocarcinoma cells) and PLC/PRF/5  (human liver hepatoma cells) 
have been used to isolate HAstV directly from faeces, however, Caco-2 cells remain the cell 
line of choice as they allow all HAstV strains to be propagated.  In the past, cell culture 
coupled with RT-PCR (ICC/RT-PCR) was used to enhance virus detection (29, 66). Today, 
with the increased sensitivity of RT-PCR, cell culture followed by RT-PCR is normally only 
performed for detection of HAstV in samples with low viral load, such as contaminated water 
samples (67). 
1.6.2   ELECTRON MICROSCOPY (EM)                                                   
Astrovirus and norovirus were first identified through EM examination of faeces from 
children with diarrhoea. For detection of these viruses, 10
6
 to 10
7
particles per gram of stool 
are required (42). During viral infection, the numbers of virions excreted are usually less than 
this. Sensitivity of EM can be increased by using antisera to clump the virus and make 
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detection easier. This method is known as immunoelectron microscopy (IEM) and was used 
to detect the first norovirus (4). Experienced technical personnel are required for EM, as only 
a small percentage of virions show typical morphology. EM is not routinely used in 
diagnostic laboratories due to high cost of equipment and lack of experienced personnel. It is 
also unsuitable for screening large numbers of specimens due to the time involved, high cost 
and low sensitivity. 
1.6.3   ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)              
The ELISA method is routinely used by most diagnostic laboratories for rapid detection of 
astrovirus and norovirus. It is rapid, has a low cost and allows screening of large numbers of 
specimens. Expensive equipment is not required, and the test is relatively easy to perform. 
Approximately 10
4
 to 10
5
 virions per gram of stool are required for detection (42). 
Commercial kits are available for detection of both viruses. Second generation ELISA kits 
have improved sensitivity and specificity. They use a group-specific monoclonal antibody to 
capture the viral antigen, followed by a biotinylated monoclonal anti-virus antibody for 
detection. The sensitivities and specificities of the ELISA test vary according to the 
commercial kit used. There are two commercial kits available for astrovirus and norovirus 
antigen detection in Australia: RIDASCREEN by R-Biopharm and IDEIA by DAKO. 
According to the manufacturers, the sensitivities compared to RT-PCR range from 76.2-
98.3% and 83.0-98.0% for astrovirus and norovirus respectively. The specificities are 
claimed to be 100% for both viruses. 
1.6.4   MOLECULAR DETECTION                                                              
Since the first development of PCR for DNA detection (68) with addition of reverse 
transcription (RT) for RNA detection (69), nucleic acid detection  has played an important 
role in diagnostic virology. PCR provides a very sensitive method to detect low levels of viral 
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DNA/RNA in specimens. For RNA detection, RT needs to be performed to generate 
recombinant DNA (cDNA) using the transcriptase before the PCR cycle. The PCR procedure 
in its simplest form involves two oligonucleotide primers that flank and define the target 
region to be amplified, and a reaction mix that contains the target nucleic acid, heat-stable 
DNA polymerase, salt solution and excess amounts of the four deoxynucleoside triphosphates 
(dNTPs).  The mix is then placed in a thermal cycler for the 3 steps of the PCR cycle: (1) 
denaturation (2) annealing and (3) extension (Figure 1.8). This cycle is repeated 20-40 times 
and that results in a 10
5
 – 106 increase in target nucleic acid concentration.                         
RT-PCR is the most sensitive assay for astrovirus and norovirus detection. The sensitivity is 
higher than ELISA; 10 to 100 virus particles per gram of stool can be detected (42). 
However, this sensitivity depends on various factors such as the primers used, RNA   
methods, reaction conditions and inhibitors. With astrovirus RT-PCR, primers from the 
highly conserved regions such as the 5’end of ORF2, the 3’ end of the genome, and the RdRp 
gene (13) are commonly selected as targets.  However, primers targeting the hypervariable 
region of ORF2 have recently been used in the confirmative tests for genotype determination 
(15, 66).                                                                                                                                  
Norovirus, primer design is more challenging due to the high genetic diversity of the viral 
genotypes. Usually two seperate primer pairs are used to detect genogroups I and II. Different 
conserved regions of the genome have been targeted with varying success, including region A 
(RdRp gene, ORF1), region B (the 3’ end of ORF1), region C (5’ end of ORF2) and region D 
(3’end of ORF2). Recent studies favour the use of region C as the target for reliable 
genotyping of GI and GII noroviruses as VP1 (ORF2) is the reference genomic region for 
establishing genotypes  (70-72). Moreover, phylogenetic analysis of region C sequences 
appears to give better strain identity and distinct clusters.                                                                                                                               
The performance of RT-PCR assays can be effected by inhibitors present in clinical 
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specimens (73). Stool specimens, for example, may contains inhibitors such as haemoglobin, 
anticoagulants, glycogen, fats, bacteria and drugs. Incomplete removal of these substances 
during nucleic acid extraction would lead to inhibition of the RT-PCR and hence false 
negative results. While nucleic acid extraction techniques, either manual or automated, 
usually are able to eliminate most inhibitors from specimens, laboratories using molecular 
assays must have methods to detect the presence of inhibitors.                                                  
Many diagnostic laboratories are now using RT-PCR for detection. However, there are many 
laboratories that do not use RT-PCR for routine diagnostic testing due to the fact that 
dedicated areas are needed for RT-PCR testing and equipment is expensive.  
 
1.7   REVERSE TRANSCRIPTION-PCR 
1.7.1.  REVERSE TRANSCRIPTION PCR (RT-PCR) PRINCIPAL 
1.7.1.1  Reverse Transcription (RT)                                                                     
RNA does not act as a template for PCR and must be converted into cDNA in the presence of 
reverse transcriptase e.g. SuperScript 
TM 
III and random hexamers or poly-(dT) 
oligonucleotides as primers (Figure 1.8). The cDNA synthesis cycle is usually performed at 
45-60°C for 15-30 minutes. The RT process is performed in a thermal cycler, usually as a 
one step process. RT and amplification are performed consecutively in one tube. Both 
processes can also be performed as a two -step process with RT and amplification performed 
in separate tubes. 
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Figure 1.8   Principle of RT-PCR 
A reverse transcriptase is used for primer-directed transcription of RNA into first-strand cDNA. Then 
a DNA polymerase is used to amplify the cDNA. The RT-PCR process can be either a one-step 
process with reverse transcription and amplication performed in one tube, or a two-step process where 
each step is performed in separate tubes. This figure adapted from Roche Diagnostic PCR Application 
Manual, 2006 (74)         
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1.7.1.2   Polymerase Chain Reaction (PCR) amplification                             
Step 1: Denaturation                                                                                            
Heating is used to dissassociate the above double stranded DNA into two single strands, 
usually 94-97°C for 15 seconds. This separation occurs because the hydrogen bonds linking 
the two DNA strands are weak and break at high temperature.                                                                 
Step 2: Annealing                                                                                             
Annealing of the primers to the target DNA usually takes place between 40-65°C for 30 
seconds, depending on the length and sequence of the primers.  Primers are usually short, 
approximately 20-30 bases with a %G+C content of 35-60%. This primer length gives 
specificity, easily binding at the annealing temperature.  Primers can be “specific” with a 
given sequence of G,A,T,C bases or “degenerate”  if some of the sequence positions have 
several possible bases. Degenerate primers are used if there is high target sequence diversity. 
The standard nomenclature for mixed base codes is: B (G,C or T), H (A,C,or T), K (G or T), 
R (A or G), S (G or C), W (A or T), Y (C or T), N=any base (75).                                                                                                            
Step3: Extension                                                                                               
Temperature is raised to 68-72°C for 1 minute and a thermal stable polymerase, such as Taq 
DNA polymerase, synthesises a new strand of DNA complementary to the original target 
DNA strand. The polymerase does this by facilitating the binding and joining of 
complementary dNTPs. Synthesis begins at the 3’ end of the primer and proceeds in the 5’ to 
3’ direction. At the end of the first PCR cycle, there are two new DNA strands that are 
identical to the original target sequence. This first round product is of indeterminate length 
and it is not until the second cycle that a discrete double-stranded product, exactly the length 
between the primer ends is synthesised (76). Each strand is complementary to one of the two 
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primers and can act as a template in subsequent cycles. Usually 30-40 PCR cycles are 
performed and as a result, up to a billion copies of the original target can be generated within 
a few hours. At the end of the PCR cycles, there is usually a final extension step at 68-72°C 
for 5-10 minutes. 
1.7.1.3  Polymerase Chain Reaction (PCR) Product Detection                                
The amplified DNA (amplicon) can be detected by a variety of methods such as agarose gel 
electrophoresis and capillary electrophoresis.  Conventional agarose gel electrophoresis is 
achieved by staining with ethidium bromide or SYBR green and direct visualisation under 
UV light (77). Usually a 1-2% agarose gel is used with 1X TBE buffer (Tris, boric acid and 
EDTA) for electrophoresis. Gel electrophoresis units work as simple electric circuits. DNA 
product is pipetted into wells on the gel and when voltage is applied, negatively charged 
DNA product migrates through the gel to the positively charged end. Migration distance is 
determined by the molecular weight. Smaller molecular weight products travel further on the 
gel. DNA Markers with known molecular size are run on the gel to allow for sizing of the 
DNA fragments. When the electrophoresis is completed, the fragments are viewed under UV 
light. Capillary electrophoresis is a popular method for detection as it allows for a faster 
separation based on size. Samples are automatically loaded into individual capillaries of 
precast gel cartridges. As with conventional electrophoresis, the negatively charged nucleic 
acids migrate through the capillary to the positively charged end. As they migrate through the 
capillary, they pass a detector which detects and measures the fluorescent signal.  The 
emission signal is converted to electronic data which is displayed as an electropherogram or 
gel image (78). 
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1.7.2   NESTED PCR                                                                                                              
Nested PCR is a popular modification as it increases sensitivity and specificity of the PCR 
reaction. It is employed in conjunction with RT-PCR by many researchers (14, 79). In a 
typical protocol, a first round amplification is performed with a single primer pair and this 
amplified product is transferred to a new reaction tube for a second round of amplification. 
The second primer pair are specific for the internal sequence amplified by the first primer 
pair. The second round product is usually detected by gel or capillary electrophoresis. The 
main disadvantage of nested PCR is the possibility of carryover or amplicon contamination. 
This can be reduced by adhering to good sterile technique, as used in Virology laboratories, 
and performing each PCR step in the correct designated laboratory area. 
1.7.3  RT-PCR IN DIAGNOSTIC LABORATORIES                                       
RT-PCR testing is performed within three physically separated laboratory areas: the pre-PCR 
area, template addition area and post PCR area. Traffic flow should follow this order and 
dedicated laboratory gowns are worn in each area. The Pre-PCR area (PCR Area 1) is a 
nucleic acid-free environment where reaction mixes and other PCR reagents are prepared. 
The template addition area (PCR Area 2) is where all sample preparation, handling 
procedures and addition to reaction mixes are performed. Personnel should only travel from 
PCR Area 2 to PCR Area 3.  Gloves should be changed regularly and decontamination of 
work surfaces, pipettes and pipette tips with disinfectant is required. The post PCR area (PCR 
Area 3) is used for PCR amplification, and detection and analysis of PCR products. Used 
amplicons should be disposed into decontamination containers to prevent cross 
contamination. 
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     1.8   AIMS AND HYPOTHESIS 
The aim of this research project was to study the role of astrovirus and norovirus in 
gastroenteritis infections in children at The Children’s Hospital at Westmead (CHW) post 
rotavirus vaccine introduction. This involved analysing infection rates, seasonal distributions, 
age distributions, patient types, nosocomial infections, viral genotypes and phylogenetic 
analysis. Faecal specimens were tested over a two year period: January 2009 to December 
2010. All specimens were screened for astrovirus and norovirus antigens by the ELISA 
method. Positive specimens were tested by RT-PCR based assays and genotypes determined 
by analysis of the PCR products. Phylogenetic analysis was performed when all genotypes 
had been determined. The sensitivity and specificity of the ELISA tests versus the RT-PCR 
based assays was tested with positive and negative specimens from both ELISA tests during 
selected months of the year. To date, no study has been performed post rotavirus vaccine 
introduction to analysis its effect on the prevalence of astrovirus and norovirus infections. 
Prior to vaccine introduction  in hospitalised children, worldwide, rotavirus was responsible 
for 20-60% infection, norovirus 3.5-29.3% and astrovirus 1.8-16.0%  (80). Since the 
successful introduction of rotavirus vaccines, rotavirus activity has diminished. The CDC has 
reported a greater than 50% decrease in infection (81). At CHW, from a prevaccine activity 
of 16.1% (years 2001-2006), rotavirus dropped to 4.9% in 2007 (vaccine started July 2007) 
and to 3.0% in 2008 (first full year of vaccination). There have been many reports in 
Australia and overseas on rotavirus activity since vaccine introduction, however, the activity 
of norovirus and astrovirus now needs to be analysed. We wanted to assess whether the 
activity of these two viruses had increased with the decrease in rotavirus activity. From our 
analysis over a two year period, we hoped to determine the prevalence and nature of 
infections with these two viruses. The development of RT-PCR methodology, enabled the 
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assessment of sensitivity and specificity of ELISA versus RT-PCR tests and determined the 
most suitable test for routine diagnostic use. 
 
1.9   RESEARCH PLAN 
I.  Astrovirus and norovirus ELISA screening of faecal specimens from patients                   
with diarrhoeal symptoms over a two year period: January 2009 – December 2010 
II.        Development of a reverse transcription-PCR (RT-PCR) based assay for astrovirus 
 detection. 
III.       Testing of positive astrovirus ELISA faecal specimens for astrovirus RNA by the RT-
 PCR based assay. 
IV. Development of reverse transcription-PCR (RT-PCR) based assays for norovirus 
 detection. 
V. Testing of positive norovirus ELISA faecal specimens for norovirus RNA by RT-
 PCR based assays. 
VI. Sequencing of PCR products for astrovirus and norovirus genotyping and    
phylogenetic analysis. 
VII. Testing of negative ELISA specimens to determine the sensitivity and specificity of    
ELISA versus RT-PCR testing for both viruses. 
VIII. Evaluation of results.                              
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2.1  MATERIALS 
2.1.1  REAGENTS AND SOURCES  
                                                                                                                           
Table 2.1  Reagents and sources 
 
METHOD SOURCE 
ELISA kits: RIDASCREEN® Astrovirus   
ELISA plate RIDASCREEN® Norovirus   
Positive control R-Biopharm, Darmstadt, Germany 
Diluent 1  
Wash Buffer  
Conjugate 1  
Conjugate 2  
Substrate  
Stop Reagent  
  
RNA extraction reagents  
0.45%  sterile Saline Cardinal Health, Dublin, USA 
MagNA Pure Compact RNA Isolation Kit Roche Diagnostics, Mannheim, Germany 
  
PCR reagents  
SuperScript™III One-Step RT-PCR System    
with Platinum®Taq DNA polymerase: 
Invitrogen, Carlsbad, Germany 
       Superscript™III RT/Platinum® Taq Mix  
       2X Reaction Mix  
       5-mM Magnesium Sulfate  
AmpliTaq Gold
®
 PCR Master Mix Applied Biosystems, Foster City, USA 
Primers (see Table 2.2) Sigma-Aldrich, Castle Hill, Australia 
MilliQ Water Department of Biochemical Genetics, CHW 
  
Gel Electrophoresis reagents  
TBE (Tris,Borate and EDTA) buffer Promega, Madison, USA 
SYBR Safe DNA gel stain  Invitrogen, Carlsbad, Germany 
Agarose Promega, Madison, USA  
Blue/orange 6X Loading Dye Promega, Madison, USA 
Bench top DNA size marker – 100bp ladder Invitrogen, Carlsbad, Germany 
  
Capillary Electrophoresis reagents  
1X Reaction Mix In-house prepared from above 2X 
QX DNA Size Marker- pUC/HaeIII (50µl) QIAGEN, Hilden, Germany 
QX Alignment Marker- 15bp/1kb (1.5ml) QIAGEN, Hilden, Germany 
  
DNA Purification reagents  
Exonuclease I Epicentre, Madison, USA 
Rapid Alkaline Phospatase Roche Diagnostics, Mannheim, Germany 
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2.1.2  ELISA REAGENTS                                                                                                  
The RIDASCREEN® Astrovirus and Norovirus ELISA kits came as ready-to-use kits with  
no reagent preparation. The kits consisted of an:                                                                                      
ELISA plate – 96 wells coated with monoclonal antibodies against astrovirus or noroviruses    
Positive Control – 1.8ml recombinant astrovirus or norovirus antigens                                         
Diluent 1 – 100ml protein-buffered NaCl solution                                                                            
Wash Buffer – 100ml phosphate-buffered NaCl solution                                                           
Conjugate 1 – 10ml biotin conjugated antibodies against astroviruses or noroviruses               
Conjugate 2 – 10ml polystrepavidin peroxidise conjugate                                                          
Substrate – 10ml hydrogen peroxide/TMB solution                                                                           
Stop Reagent – 0.5M sulphuric acid solution 
 
2.1.3  RNA EXTRACTION  REAGENTS                                                       
2.1.3.1  0.45% Sterile Saline                                                                             
Ready- to- use 0.45% sterile saline was stored at room temperature. It was dispensed into a            
20ml aliquot for routine daily use. The portion of the aliquot not used was discarded at the 
end of sample preparation to minimise contamination. 
2.1.3.2  MagNA Pure Compact RNA Isolation Kit                                           
Isolation kits contained ready-to-use reagent cartridges, tip trays, DNase solution, sample and 
elution tubes. Kits were stored at 4-8°C. These kits were used for automated RNA extraction 
in the MagNA Pure Compact instrument. These kits are routinely used for the extraction of 
RNA from diagnostic stool specimens in the Department of Infectious Diseases and 
Microbiology, CHW. 
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2.1.4  PCR REAGENTS 
2.1.4.1   SuperScript™III One-Step RT-PCR System with  
    Platinum®Taq DNA polymerase: 
 
Kit components were Superscript™III RT/Platinum® Taq Mix, 2X Reaction Mix and 5-mM 
Magnesium Sulfate.  The 2X Reaction Mix was a buffer containing 0.4mM of each dNTP 
and 3.2 mM MgSO4, optimised for RT-PCR. A 5- mM Magnesium Sulfate vial was provided 
to increase Mg
2+
 concentration if required. The Superscript™III RT enzyme component  
synthesized cDNA at 45°C-60°C and the Platinum® Taq polymerase activated at 94°C to 
provide a “hot start” PCR for increased sensitivity and specificity. The kit was stored at          
-20°C.  
2.1.4.2   AmpliTaq Gold
®
 PCR Master Mix                                                   
The Master Mix was a ready-to-use 2X concentrate containing 0.05U/µl AmpliTaq Gold             
DNA Polymerase, GeneAmp PCR Gold Buffer, 400µM of each dNTP and 5mM MgCl2. 
Recommended activation temperature was 95°C, providing a “hot start” PCR for increased 
sensitivity/specificity. The Master Mix was stored at 4-8°C.  
2.1.4.3  Primers                                                                                                  
The oligonucleotide primers for detection of all human astroviruses (HAstV) and noroviruses 
(NoV) are presented in Table 2.2. These primers were directed against conserved regions of 
the viral genomes. The astrovirus primers targeted the 5’ end of the open reading frame 2 
(ORF2) capsid protein precursor gene. The norovirus primers targeted the non-coding 
junction region (region C) between the RNA-dependent RNA polymerase (RdRp) gene of the 
open reading frame 1 (ORF1) and the capsid N/S domain at the 5’ end of ORF2 capsid 
protein gene. First-round RT-PCR primers were commercially available primers. Second-
round nested PCR (nPCR) primers were internal to the first round primers and developed in-
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house using Primer-BLAST design tool software from the US National Center for 
Biotechnology Information (NCBI). The primer positions are shown on reference sequences 
from the Genbank database (NCBI) with analysis performed using BLAST software (Table 
2.2). 
Table 2.2  Oligonucleotide primers for first round RT-PCR and second round nPCR 
PCR PRIMER SEQUENCE  
5’-3’ 
 
GENOME 
POSITION 
AMPLICON  
  SIZE (bp) 
REF. 
AST  
RT-PCR 
MON269 CAACTCAGGAAACAGGGTGT 4529-4548a 449 (13) 
 MON270 TCAGATGCATTGTCATTGGT 4958-4977a  (13) 
      
AST  
nPCR 
ASTIF GGAAACAGGGTGTCACAGGACCA 
 
4536-4558a 329 in-house 
 ASTIR ACGTGCGCCTAATCCTGACCA 4844-4864a  in-house 
      
NOR GI 
RT-PCR 
G1-SKF CTGCCCGAATTYGTAAATGA 5342-5361b 330 (70) 
 G1-SKR CCAACCCARCCATTRTACA 5653-5671b  (70) 
      
NOR GII 
RT-PCR 
COG2F CARGARBCNATGTTYAGRTGGATGAG 5003-5028c 387 (82) 
 G2-SKR CCRCCNGCATRHCCRTTRTACAT 5367-5389c  (70) 
      
NOR GI 
nPCR 
NOR1IF ATTGACCCTGTGGCTGGCTCCT 5451-5472d 150 in-house 
 NOR1IR ATCAAAAAGCACATCACCGGGGGT 5577-5600d  in-house 
      
NOR GII 
nPCR 
NOR2IF GATCTGAGCACGTGGGAGGGC 
 
5036-5056e 242 in-house 
 NOR2IR TGAACTCTCCACCAGGGGCTTGT 5255-5277e  in-house 
      
B: C, G or T, H: A, C or T, R: A or G, Y: C or T, N: any base 
 
a Position in astrovirus genomic sequence L23513 
bPosition in norovirus genomic sequence M87661 
c Position in norovirus genomic sequence X86557 
d Position in norovirus genomic sequence AJ277615 
e  Position in norovirus genomic sequence EF126965 
2.1.4.3.1 Astrovirus Primer Selection                                                          
Astrovirus First Round Reverse Transcription-PCR (RT-PCR) Primers                                                        
The sequences of the forward primer: MON269 and reverse primer: MON270 and their 
alignment with the genome of reference strains from HAstV genotypes 1-8 are shown in 
Table 2.3. The primer pair positions are shown for the available full genome sequences of 
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HAstV 1-6 and 8 genotypes. As the complete genome of HAstV-7 has not been fully 
sequenced to date, the primer pair position on the capsid protein precursor gene (ORF2) is 
shown. The primer pair was aligned at very similar positions on the genomes; only differing 
by five nucleotides amongst the genotypes. The forward primer, MON269, was aligned at the 
5’ end between positions 4524 to 4529 and between 4543 and 4548 at the 3’ end.  Likewise, 
the reverse primer, MON270, was aligned at the 5’ end between positions 4972 and 4977 and 
at the 3’ end between positions 4953 and 4958. Primer MON269 showed 100%  homology 
with the capsid protein precursor sequences of six genotypes: HAstV-1,2,3,5,6,7 and 95% 
homology (1 nucleotide difference) with two genotypes: HAstV-4 and 8. Primer MON270 
showed a 80-100% homology (0 to 4 nucleotide difference) between the eight genotype 
sequences: 100% with HAstV-2 and 5; 95% with HAstV-1,6 and 7;  90% with HAstV-8; 
85% with HAstV-3; and 80% with HAstV-4.                                                                                              
                                                       5’                     3’ 
MON269 1 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
20              
HAstV-1 4529 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
4548 
HAstV-2 4526 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
4545 
HAstV-3 4528 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
4547 
HAstV-4 4528 CAACTCAGGAAACAAGGTGT 
|||||||||||||||||||| 
4547 
HAstV-5 4524 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
4543 
HAstV-6 4529 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
4548 
HastV-7 231 CAACTCAGGAAACAGGGTGT 
|||||||||||||||||||| 
250 
HAstV-8 4527 CAACTCAGGAAACAAGGTGT 4546 
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       5’                     3’ 
MON270 1 TCAGATGCATTGTCATTGGT 
|||||||||||||||||||| 
20 
HAstV-1 4977 TCAGATGCATTGTCGTTGGT 
|||||||||||||||||||| 
4958 
HAstV-2 4974 TCAGATGCATTGTCATTGGT 
|||||||||||||||||||| 
4955 
HAstV-3 4976 TCTGAAGCATTGTCATTTGT 
|||||||||||||||||||| 
4957 
HAstV-4 4976 TCTGAAGCATTATCATTTGT 
|||||||||||||||||||| 
4957 
HAstV-5 4972 TCAGAAGCATTGTCATTGGT 
|||||||||||||||||||| 
4953 
HAstV-6 4977 TCTGAAGCATTGTCATTGGT 
|||||||||||||||||||| 
4958 
HAstV-7 679 TCAGATGCATTATCATTAGT 
|||||||||||||||||||| 
660 
HAstV-8 4975 TCTGAAGCATTGTCATTTGT 4956 
    
 
Table 2.3  Sequence alignments of HAstV first round RT-PCR primers: MON269 and MON 270  
with reference sequences from the complete genomes of HAstV genotypes 1-6 and 8, and the  
capsid protein precursor of HAstV genotype 7. The reference Genbank Accession numbers are: 
HAstV1(L23513), HAstV-2 (L13745), HAstV-3 (JF491430), HAstV-4 (AY720891), HAstV-5 
(JQ403108), HAstV-6 (HM237363), HAstV-7 (Y08632) and HAstV-8 (AF260508) 
 
Astrovirus Second Round Nested PCR (nPCR) Primers                                                                                  
The sequences of the forward primer: ASTIF and reverse primer: ASTIR and their alignment 
with the genome of reference strains from HAstV genotypes 1-8 are shown in Table 2.4. 
Genbank database reference strains were the same as those used for MON269, MON270 
primer analysis. The forward primer, ASTIF, was aligned at the 5’ end between positions 
4531 to 4537 and between 4553 and 4559 at the 3’ end.  Likewise, the reverse primer, 
ASTIR, was aligned at the 5’ end between positions 4859 and 4865 and at the 3’ end between 
positions 4839 and 4845. Primer ASTIF showed 100%  homology with the capsid protein 
precursor sequences of six genotypes: HAstV-1,2,3,5,6,7 and 96% homology (1 nucleotide 
difference) with two genotypes: HAstV-4 and 8. Primer ASTIR showed a 71-100% 
homology (0 to 6 nucleotide difference) between the eight genotype sequences: 100% with 
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HAstV-5; 95% with HAstV-1; 81% with HAstV-8; 76% with HAstV-2,3,6,and 7; and 71% 
with HAstV-4.  
                            5’                    3’ 
ASTIF 1 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
23 
HAstV-1 4536 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4558 
HAstV-2 4533 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4555 
HAstV-3 4535 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4557 
HAstV-4 4535 GGAAACAAGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4557 
HAstV-5 4531 GGAAACAAGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4553 
HAstV-6 4537 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
4559 
HastV-7 238 GGAAACAGGGTGTCACAGGACCA 
||||||||||||||||||||||| 
260 
HAstV-8 4534 GGAAACAAGGTGTCACAGGACCA 4556 
 
 
   
                                                            5’                      3’ 
ASTIR 1 ACGTGCGCCTAATCCTGACCA 
||||||||||||||||||||| 
21 
HAstV-1 4864 ACGCGCACCTAATCCTGACCA 
||||||||||||||||||||| 
4844 
HAstV-2 4861 ACGAGCACCAAGTCCAGACCA 
||||||||||||||||||||| 
4841 
HAstV-3 4863 ACGGGCTCCTAGCCCAGACCA 
||||||||||||||||||||| 
4843 
HAstV-4 4863 GCGCGCTCCAAGCCCAGACCA 
||||||||||||||||||||| 
4843 
HAstV-5 4859 ACGTGCGCCTAATCCTGACCA 
||||||||||||||||||||| 
4839 
HAstV-6 4865 GCGGGCCCCCAGTCCTGACCA 
||||||||||||||||||||| 
4845 
HAstV-7 560 GCGGGCACCAAGTCCTGACCA 
||||||||||||||||||||| 
546 
HAstV-8 4862 ACGTGCTCCGAGTCCAGACCA 4842 
    
 
Table 2.4  Sequence alignments of HAstV second round nPCR primers: ASTIF and ASTIR with   
 reference sequences from the complete genomes of HAstV genotypes 1-6 and 8, and the capsid   
 protein precursor of HAstV genotype 7. The reference Genbank Accession numbers are:            
 HAstV-1(L23513), HAstV-2 (L13745), HAstV-3 (JF491430), HAstV-4 (AY720891),               
 HAstV-5 (JQ403108), HAstV-6 (HM237363), HAstV-7 (Y08632) and HAstV-8 (AF260508) 
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  2.1.4.3.2  Norovirus Primer Selection                                                          
Norovirus GI First Round Reverse Transcription-PCR (RT-PCR) Primers                                                        
The sequences of the primer pair: forward primer G1-SKF/reverse primer G1-SKR  and their 
alignment with the genome of reference strains of NoV genotypes GI.1-6,GI.8, GI.9 are 
shown in Table 2.5. The primer pair positions are shown for the available full genome 
sequences, with the exception of GI.3 and GI.5 NoV genotypes. As the complete genomes of 
NoV genotypes GI.3 and GI.5 have not been fully sequenced to date, the primer pair position 
on region C are shown. The primer pair was aligned at similar positions on the full genomes; 
differing by 15 nucleotides amongst the genotypes. The forward primer, G1-SKF, was 
aligned at the 5’ end between positions 5327 to 5342 and between 5346 and 5361 at the 3’ 
end.  Likewise, the reverse primer, G1-SKR, was aligned at the 5’ end between positions 
5656 and 5671 and at the 3’ end between positions 5638 and 5653. Primer G1-SKF showed 
100% homology with the region C sequences of five NoV genotypes: GI.1, GI.2, GI.5, GI.6, 
GI.9, 95% homology (1 nucleotide difference) with two NoV genotypes: GI.4 and GI.8 and 
90% homology (2 nucleotide difference) with one NoVgenotype: GI.3. Primer G1-SKR 
showed a 95-100% homology (0 to 1 nucleotide difference) between the eight NoV genotype 
sequences: 100% with GI.1, GI.3, GI.5, GI.8, GI.9 and 95% with GI.4 and GI.6.    
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                           5’                     3’ 
G1-SKF 1 CTGCCCGAATTYGTAAATGA             
||||||||||||||||||||   
20              
GI.1 5342 CTGCCCGAATTCGTAAATGA 
|||||||||||||||||||| 
5361 
GI.2 5339 CTGCCCGAATTTGTAAATGA 
|||||||||||||||||||| 
5358 
GI.3 784 CTGCCCGATTATGTAAATGA 
|||||||||||||||||||| 
803 
GI.4 5330 TTGCCCGAATTCGTAAATGA 
|||||||||||||||||||| 
5349 
GI.5 556 CTGCCCGAATTCGTAAATGA 
|||||||||||||||||||| 
575 
GI.6 5327 CTGCCCGAATTCGTAAATGA 
|||||||||||||||||||| 
5346 
GI.8 5339 CTACCCGAATTTGTAAATGA 
|||||||||||||||||||| 
5358 
GI.9 5336 CTGCCCGAATTCGTAAATGA 5355 
 
 
   
                           5’                     3’ 
G1-SKR 1 CCAACCCARCCATTRTACA 
||||||||||||||||||| 
19 
GI.1 5671 CCAACCCAGCCATTATACA 
||||||||||||||||||| 
5653 
GI.2 5668 CCAACCCAGCCATTATACA 
||||||||||||||||||| 
5650 
GI.3 1113 CCAACCCAACCATTGTACA 
||||||||||||||||||| 
1095 
GI.4 5659 CCAACCCAACCATTATACG 
||||||||||||||||||| 
5641 
GI.5 885 CCAACCCAGCCATTATACA 
||||||||||||||||||| 
867 
GI.6 5656 CCAACCCATCCATTGTACA 
||||||||||||||||||| 
5638 
GI.8 5668 CCAACCCAACCATTATACA 
||||||||||||||||||| 
5650 
GI.9 5665 CCAACCCAACCATTATACA 5647 
    
 
Table 2.5  Sequence alignments of NoV GI first round RT-PCR primers: G1-SKF and G1-SKR with   
 reference sequences from the complete genomes of NoV genotypes GI.1,GI.2,GI.4,GI.6,GI.8,GI.9 
and partial genomes of GI.3 and GI.5. The reference Genbank Accession numbers are: GI.1(M87661), 
GI.2 (L07418), GI.3 (U04469), GI.4 (AB042808), GI.5 (AF414406), GI.6 (AF093797), GI.8 
(AB081723) and GI.9 (AB039774). Within primer sequences, nucleotides R: A or G and Y: C or T 
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Norovirus GII First Round Reverse Transcription-PCR (RT-PCR) Primers                                              
The sequences of the primer pair: forward primer COG2F/reverse primer G2-SKR  and their 
alignment with the genome of reference strains of NoV genotypes GII.2-6,GII.7, GII.9 and 
GII.12 are shown in Table 2.6. The primer pair positions are shown for the full genome 
sequence of NoV genotype GII.4 , and partial genome sequences of  NoV genotypes GII.2, 
GII.3, GII.5 to GII.7, GII.9 and GII.12.  As the complete genomes of these NoV genotypes 
have not been fully sequenced to date, the primer pair positions on reference Genbank 
sequences are shown. Primer COG2F showed 100% homology with the reference sequences 
of all eight NoV genotypes. Primer G2-SKR showed 100% homology with seven NoV 
genotype sequences, the exception being genotype GII.7 with 95% homology (1 nucleotide 
difference).    
                            5’                            3’ 
COG2F 1 CARGARBCNATGTTYAGRTGGATGAG             
||||||||||||||||||||||||||   
26              
GII.2 901 CAAGAACCCATGTTCAGATGGATGAG 
|||||||||||||||||||||||||||| 
926 
GII.3 769 CAAGAGTCAATGTTCAGGTGGATGAG 
|||||||||||||||||||||||||| 
794 
GII.4 5003 CAAGAGCCAATGTTCAGATGGATGAG 
|||||||||||||||||||||||||| 
5028 
GII.5 686 CAAGAGCCTATGTTCAGGTGGATGAG 
|||||||||||||||||||||||||| 
711 
GII.6 490 CAAGAGGCCATGTTTAGGTGGATGAG 
|||||||||||||||||||||||||| 
515 
GII.7 490 CAAGAGGCCATGTTCAGGTGGATGAG 
|||||||||||||||||||||||||| 
515 
GII.9 771 CAAGAGGCCATGTTTAGGTGGATGAG 
|||||||||||||||||||||||||| 
796 
 
GII.12 490 CAAGAGCCAATGTTCAGATGGATGAG  515 
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                            5’                        3’                      
G2-SKR 1 CCRCCNGCATRHCCRTTRTACAT 
||||||||||||||||||||||| 
 23 
GII.2 1287 CCACCGGCATACCCGTTATACAT 
||||||||||||||||||||||| 
1265 
GII.3 1155 CCACCTGCATAACCATTGTACAT 
||||||||||||||||||||||| 
1133 
GII.4 5389 CCACCTGCATAACCATTGTACAT 
||||||||||||||||||||||| 
5367 
GII.5 1072 CCACCCGCATAACCATTGTACAT 
||||||||||||||||||||||| 
1050 
GII.6 876 CCACCAGCATATCCATTGTACAT 
||||||||||||||||||||||| 
854 
GII.7 876 CCACCAGCGTGCCCATTATACAT 
||||||||||||||||||||||| 
854 
GII.9 
 
1157 CCACCGGCATACCCGTTATACAT 
||||||||||||||||||||||| 
1135 
GII.12 876 CCACCTGCATAACCATTATACAT  854 
 
 
Table 2.6  Sequence alignments of NoV first round GII RT-PCR primers: COG2F and G2-SKR with   
 reference sequences from the complete genome of NoV genotype GII.4 and partial genomes of 
NoVgenotypes GII.2,GII.3,GII.5,GII.6,GII.7, GII.9 AND GII.12. The reference Genbank Accession 
numbers are: GII.2(X81879), GII.3 (U02030), GII.4 (X86557), GII.5 (AF397156), GII.6 (AF414407), 
GII.7 (AF414409), GII.9 (AY038599), GII.12 (AF414420). Within primer sequences, B: C,G,T and 
H: A,C or T,and R: A or G, Y: C or T and N: any base 
 
Norovirus Second Round GI Nested PCR and GII Nested PCR Primers                                                                                  
The sequences of the primer pairs: NOR1IF/NOR1IR and NOR2IF/NOR2IR and their 
alignments with the genome of reference strains from NoV genotypes GI.1-6, 8 9 and GII.2-
7,9,12  are shown in Tables 2.7 and 2.8 respectively. Genbank database reference strains 
were the same as those used for G1-SKF/G1-SKR, COG2F/G2-SKR primer analysis. The GI 
forward primer, NOR1IF, was aligned at the 5’ end between positions 5439 to 5454 and 
between 5460 and 5475 at the 3’ end.  Likewise the GI the reverse primer, NOR1IR, was 
aligned at the 5’ end between positions 5588 and 5603 and at the 3’ end between positions 
5565 and 5580. The GII forward primer, NOR2IF, was aligned at the 5’ end between 
positions 4531 to 4537 and between 4553 and 4559 at the 3’ end.  Likewise the GII reverse 
primer, NOR2IR, was aligned at the 5’ end between positions 4859 and 4865 and at the 3’ 
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end between positions 4839 and 4845. NOR1IF showed 100% homology with NoV genotype 
GI.4,  and a 67-87% homology (3-7 nucleotide difference) with NoV genotypes: GI.1-3,5,6,8 
and 9. Primer NOR1IR showed a 100% homology with NoV GI.4 and a 76-88% homology 
(3 to 6 nucleotide difference) between the NoV GI.1-3, 5, 6, 8 and 9.  NOR2IF showed a 100% 
homology with GII.4,6 and 12 and a 86-95% homology (1-3 nucleotide difference) with 
GII.2-7,9 and 12. NOR2IR showed a 100% homology with GII.4, and a 70-87% homology 
with GII.2-7,9 and12.     
                            5’                   3’ 
NOR1IF 1 ATTGACCCTGTGGCTGGCTCCT             
||||||||||||||||||||||   
 22              
GI.1 5454 ATGGATCCTGTAGCAGGTTCTT 
|||||||||||||||||||||| 
5475 
GI.2 5451 ATGGAACCCGTGGCCGGGCCAA 
|||||||||||||||||||||| 
5472 
GI.3 896 ATGGAGCCAGTGGCTGGGGCTG 
|||||||||||||||||||||| 
917 
GI.4 5442 ATTGACCCTGTGGCTGGCTCCT 
|||||||||||||||||||||| 
5463 
GI.5 668 CTTGATCCTGTGGCTGGGGCTT 
|||||||||||||||||||||| 
689 
GI.6 5439 ATGGATCCTGTTGCGGGTGCTT 
|||||||||||||||||||||| 
5460 
GI.8 5451 ATGGACCCTGTTGCGGGTGCTT 
|||||||||||||||||||||| 
5472 
GI.9 5448 CTTGATCCTGTGGCTGGGGCTT 
 
5469 
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                            5’                         3’ 
NOR1IR 1 ATCAAAAAGCACATCACCGGGGGT 
|||||||||||||||||||||||| 
 24 
GI.1 5603 ATCAAACAAAACATCACCGGGGGT 
|||||||||||||||||||||||| 
5580 
GI.2 5600 ATCAAACAAAATATCACCGGGGGT 
|||||||||||||||||||||||| 
5577 
GI.3 1045 GTCAAATAAAATGTCACCGGGTGT 
|||||||||||||||||||||||| 
1022 
GI.4 5591 ATCAAAAAGCACATCACCGGGGGT 
|||||||||||||||||||||||| 
5568 
GI.5 817 ATCAAACAGGATATCGCCGGGGGT 
|||||||||||||||||||||||| 
794 
GI.6 5588 ATCAAATAAAATATCACCGGGGGT 
|||||||||||||||||||||||| 
5565 
GI.8 5600 ATCAAACAAAATGTCACCGGGGGT 
|||||||||||||||||||||||| 
5577 
GI.9 5597 ATCAAATAATATATCACCGGGGGT 
 
5574 
 
 
   
Table 2.7  Sequence alignments of NoV GI second round nPCR primers: NOR1IF and NOR1IR with   
 reference sequences from the complete genomes of NoV genotypes GI.1, GI.2, GI.4, GI.6, GI.8, GI.9 
and partial genomes of GI.3 and GI.5. The reference Genbank Accession numbers are: GI.1(M87661), 
GI.2 (L07418), GI.3 (U04469), GI.4 (AB042808), GI.5 (AF414406), GI.6 (AF093797), GI.8 
(AB081723) and GI.9 (AB039774).  
 
                                                       5’                   3’ 
NOR2IF 1 GATCTGAGCACGTGGGAGGGC             
|||||||||||||||||||||   
21              
GII.2 934 GATTTGAGCACGTGGGAGGGC 
||||||||||||||||||||| 
954 
GII.3 802 GATCTAAGCACATGGGAGGGC 
||||||||||||||||||||| 
822 
GII.4 5036 GATCTGAGCACGTGGGAGGGC 
||||||||||||||||||||| 
5056 
GII.5 719 GACTTGAGCACGTGGGAGGGC 
||||||||||||||||||||| 
739 
GII.6 523 GATCTGAGCACGTGGGAGGGC 
||||||||||||||||||||| 
543 
GII.7 523 GACCTCAGCACATGGGAGGGC 
||||||||||||||||||||| 
543 
GII.9 804 GACCTCAGCACATGGGAGGGC 
||||||||||||||||||||| 
824 
GII.12 523 GATCTGAGCACGTGGGAGGGC 
 
543 
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                                                       5’                         3’ 
NOR2IR 1 TGAACTCTCCACCAGGGGCTTGT 
||||||||||||||||||||||| 
 23 
GII.2 1175 TAAATTCACCATTAGGGGCCTGG 
||||||||||||||||||||||| 
1154 
GII.3 1033 TAAACTCACCACCAGGTGCTTGT 
||||||||||||||||||||||| 
1021 
GII.4 5277 TGAACTCTCCACCAGGGGCTTGT 
||||||||||||||||||||||| 
5255 
GII.5 960 TAAATTCACCATTAGGGGCTTGG 
||||||||||||||||||||||| 
938 
GII.6 764 TGAACTCGCCCTGTGGTGCTTGG 
||||||||||||||||||||||| 
742 
GII.7 764 TAAACTCACCTGCAGGAGCTTGT 
||||||||||||||||||||||| 
742 
GII.9 1045 TGAATTCTCCAGCGGGTGCTTGT 
||||||||||||||||||||||| 
1023 
GII.12 794 TGAACTCTCCATTGGGTGCCTGC 
 
742 
    
Table 2.8  Sequence alignments of NoV GII second round nPCR primers: NOR2IF and NOR2IR   
 with reference sequences from the complete genome of NoV genotype GII.4 and partial genomes of 
GII.2,GII.3,GII.5, GII.6, GII.7, GII.9, GII.12. The reference Genbank Accession numbers are: 
GII.2(X81879), GII.3 (U02030), GII.4 (X86557), GII.5 (AF397156), GII.6 (AF414407), GII.7 
(AF414409), GII.9 (AY038599), GII.12 (AF414420).  
                                                               
2.1.5  PCR DETECTION REAGENTS 
2.1.5.1  Gel Electrophoresis Reagents 
2.1.5.1.1  Tris, Borate and EDTA (TBE) Buffer (10X)                                   
To make a 1X solution: 1 litre of 10X TBE buffer was added to 9 litres of MilliQ water. 
Buffer was stored at room temperature. 1X TBE was used to make agarose gel and as a gel 
electrophoresis buffer. 
2.1.5.1.2  SYBR Safe DNA Gel Stain                                                               
This reagent comes as a 10,000X concentrate in DMSO. It was used to stain DNA in agarose 
gels for detection using a UV transilluminator. Storage was at room temperature. 
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2.1.5.1.3  Agarose gel ( 1.5% and 2%)                                                           
1.5%  agarose gel was made by dissolving 1.5g of agarose in 100ml of 1X TBE buffer or 
2.0g of agarose for a 2% gel. The agarose solution was mixed and microwaved for 2-3 
minutes to get a transparent, homogenous solution. The gel was cooled in water and 5ul of 
SYBR Safe DNA gel stain (10,000X) added. The warm gel was then poured into a mould 
fitted with a comb. The gel was allowed to set at room temperature for 15-20 minutes. 
2.1.5.1.4  Blue/Orange Loading Dye                                                                 
6X Blue/Orange Loading Dye was added to the DNA sample to visualise sample migration  
through the gel and increase the density of the sample so that the DNA sank evenly into the 
gel lane. For use: 1.5µl of dye was mixed with 7.5µl of sample. Storage was at 4-8°C. 
2.1.5.1.5  DNA Molecular weight marker                                                       
Gel Electrophoresis Bench top DNA size marker – 100bp  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: 100bp DNA Ladder -2% agarose gel with  ethidium                  
           bromide. Figure adapted from Invitrogen Doc.Rev102501                   
 
The 100bp ladder consisted of 15 fragments from 100-1500bp, and an additional fragment at 
2072bp. The stock solution concentration was 1ug/ul. To make a working solution: 50uL 
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marker was diluted in 450ul MilliQ water and 150ul Blue/Orange 6X loading dye. For use in 
the gel: 6ul per lane was used. Storage was at 4-8°C.  
 
2.1.5.2  Capillary Electrophoresis Reagents 
2.1.5.2.1  1X Reaction Mix                                                                                 
An equal volume of MilliQ water was added to 2X Reaction Mix.1X Reaction Mix was 
prepared immediately before use and was not stored. 
2.1.5.2.2  QX DNA Molecular Weight Marker  
Capillary Electrophoresis DNA size marker – 80 to 587bp 
       
Figure 2.2  pUCHaeIII DNA Ladder – 20ng/µl 
QX DNA size marker pUC/HaeIII (100ng/uL) was used with 9 DNA fragments: 80, 102, 
174, 257, 267, 298, 434, 458 and 587bp. The marker was diluted according to the QIAxcel 
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method/PCR performed: AM420 method (RT-PCR) the marker concentration was 20ng/µl: 
3µl pUC/HaeIII was added to 12µl 1X Reaction Mix, AL420/ (nPCR) the marker 
concentration was 10ng/µl: 1.5µl pUC/HaeIII was added to 4.5µl 2X Reaction Mix and 9µl 
MilliQ water. The two PCR markers were analysed in the QIAxcel instrument: if the number 
of peaks corresponding to the nine DNA fragment sizes were correct the markers were saved 
as reference markers in the instrument software.  New reference markers were created when a 
new gel cartridge was installed. 
2.1.5.2.3  QX Alignment Marker                                                                      
QX Alignment Marker 15bp-1kb (1.5ml) was used with the pUC/HaeIII DNA size marker 
according to the manufacturers’ recommendation and stored at 4-8°C. Before use it was 
brought to room temperature: 15µl was added to each tube of a 12 tube strip, 1 drop of oil 
was then added to each tube, and the strip was placed into marker 1 position of the marker 
tray. When not in use the 12 tube strip was stored at -20°C and returned to room temperature 
prior to use. The alignment marker strip was replaced every three days or 50 runs, whichever 
came first.                                                                                                                                                        
2.1.6  DNA Purification reagents  
2.1.6.1  Exonuclease I                                                                                      
Exonuclease I stock concentration was 20U/µl and storage was at -20°C. It was used to clean-
up PCR product prior to sequencing by removing unincorporated primers. 
2.1.6.2  Rapid Alkaline Phosphatase                                                                               
Rapid alkaline phosphatase stock concentration was 1U/µl and storage was at -20°C. It was 
used together with Exonuclease I to clean-up PCR product prior to sequencing by removing 
unincorporated nucleotides. 
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2.1.7  Specimens                                                                                                                            
All specimens used in this study were faecal stool specimens received for diagnostic testing 
in the Department of Infectious Diseases and Microbiology at The Children’s Hospital at 
Westmead from January 2009 to December 2010. Specimens were from hospitalised children 
as well as children attending outpatient clinics and the Emergency Department. Diagnostic 
stool specimens with liquid or semisolid appearance from patients with clinical symptoms of 
diarrhoea were tested. Rectal swabs were excluded due to insufficient stool material. A total 
of 5052 stool specimens were collected over the two year period from children up to 15 years 
of age with 2494 specimens in 2009 (49.4%) and 2558 specimens in 2010 (50.6%). There 
were 2807 specimens from males (55.6%) and 2245 from females (44.4%). Specimens were 
stored at 4-8°C and prior to testing were screened for the presence of rotavirus antigens, 
adenovirus antigens and the enteric bacteria: Salmonella, Shigella, Campylobacter and 
Yersinia spp. Positive results for these viruses and bacteria did not exclude specimens from 
this study. Astrovirus and norovirus PCR positive stool specimens were also obtained from 
an external source, The Microbiology Department, Centre for Infectious Diseases and 
Microbiology Laboratory Services (CIDMLS), Institute of Clinical Pathology and Medical 
Research (ICPMR), Westmead Hospital for use in test validation. 
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2.2  METHODS 
2.2.1  Introduction                                                                                            
Faecal specimens received in the Department of Infectious Diseases and Microbiology at 
CHW from January, 2009 to December, 2010 from children presenting with diarrheal 
symptoms were used in this study.  Specimens were from hospitalised children as well as 
children attending outpatient clinics and the Emergency Department. All specimens were 
screened for astrovirus and norovirus antigens using commercial ELISA kits. Molecular 
assays were developed in-house to detect astrovirus and norovirus RNA. Positive ELISA 
specimens had RNA extracted and the relevant nRT-PCR assay was then performed. PCR 
products were visualised using conventional or capillary electrophoresis. Positive DNA 
products with the correct band size were purified and sent for sequence analysis. Genotypes 
were determined by sequence comparison to reference strains in Genbank. Phylogenetic 
analysis was used to create multiple sequence alignments and phylogenetic trees. A number 
of negative ELISA specimens were randomly selected and tested by the nRT-PCR assays. 
Statistical analysis was then undertaken to compare the performance of the ELISA tests to the 
nRT-PCR assays with sensitivity, specificity and confidence intervals determined. 
2.2.2  ELISA Method                                                                                     
ELISA testing for viral antigen was performed using RIDASCREEN® Astrovirus kits and 
RIDASCREEN
®
 Norovirus kits by R-Biopharm (Darmstadt, Germany). These kits were in a 
ready-to-use format and all steps were performed according to the manufacturers’ 
instructions. The ELISA kits utilised a sandwich-type method summarised in the following 
steps: the microwell plates pre-coated with monoclonal antibodies to all known astrovirus or 
norovirus serotypes were brought to room temperature. Test stool suspensions were prepared 
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using 100µl (liquid stool) or 100mg (semi-solid stool) in 1ml of sample dilution buffer (1:11) 
and centrifuged at 2500g for 5 minutes. Test stool supernatants and a positive control were 
pipetted into separate wells on the plate. Diluent 1 was used as a negative control. 
Biotinylated monoclonal anti-astrovirus or norovirus antibodies (Conjugate 1) was added to 
all wells and the plates were incubated for 1 hour at room temperature (20°-25°C). The plates 
were then washed with prepared Wash Buffer, polystrepavidin peroxidise conjugate 
(Conjugate 2) was added to all wells and the plates were incubated for 1 hour at room 
temperature  (20°-25°C). If astrovirus or norovirus antigens were present a sandwich complex 
of the coated well monoclonal antibodies - specimen antigen-antibody-biotin conjugate- 
polystrepavidin peroxidise conjugate would form. The plates were washed with prepared 
Wash Buffer to remove unattached Conjugate 2. Hydrogen peroxide/TMB reagent 
(Substrate) was added to each well and if astrovirus or norovirus antigens were present, the 
well solution changed from colourless to blue. The final addition of 0.5M sulphuric acid 
(Stop reagent) to each well changed the blue colour to yellow. The optical density (O.D.) was 
proportional to the quantity of virus present.  
 
Figure 2.3  Astrovirus and Norovirus Sandwich ELISA method 
                    Figure adapted from Leinco Technology Inc. Doc. Rev 
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Plates were read using a spectrophotometer at 450nm wavelength with 620nm as the 
reference filter. To interpret test results the cut-off value was calculated, and this was then 
used to calculate positive, equivocal and negative results:                                                     
Cut-off value = Negative Control O.D + 0.15                                                                           
Positive = > Cut-off + 10%,   Equivocal = Cut-off +/- 10%,   Negative = < Cut-off - 10%                                                                                                                                                                                                                                                                                                                                                             
On completion of ELISA testing, stool specimens were stored at -80°C until RNA extraction. 
2.2.3  RNA Extraction                                                                                                                   
RNA was extracted from the stool specimens using the automated extraction system, the 
MagNA  Pure Compact (Roche Diagnostics, Penzberg, Germany) using the RNA Isolation 
Kits (see 2.1.3.2). The system used magnetic bead technology with pre-filled sealed 
cartridges containing all reagents and reaction tips trays for reagent transfer. Stool 
suspensions (10% w/v) were prepared in sterile 0.45% saline, vortexed and centrifuged at 
5,000g for 5 minutes. For RNA extraction, 200µl of supernatant was pipetted into a sample 
tube, and 20µl of DNase was pipetted into a separate tube. A positive control (ELISA 
positive stool specimen) and negative control (sterile 0.45% saline) were extracted in parallel 
with the samples. Reagent cartridges, reaction tip trays, sample tubes, DNase tubes and 
extraction tubes were loaded into the instrument.                                                                               
The RNA isolation procedure involved 5 steps:                                                                                  
Step 1 – Samples were lysed by incubation with Lysis-Binding Buffer ( Proteinase K and a                                                   
chaotropic salt), which destroyed remaining proteins including nucleases.                                        
Step 2 – Magnetic Glass Particles (MGPs) were added and nucleic acids were immobilized .                                                                                                             
Step 3 – Genomic DNA was degraded by incubation with DNase.                                                    
Step 4 – Magnetic separation of the nucleic acid-bead complex                                                         
Step 5 – Washing steps removed unbound substances such as PCR inhibitors, protein, cell 
debris etc.                                                                                                                               
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Step 6 – Magnetic separation of the nucleic acid-bead complex.                                                                                                                                                                     
Step 7 – Purified total RNA was eluted from the MGPs.                                                                      
The Average RNA yield eluted from a faeces specimen was not provided by the 
manufacturer, however, for whole blood it was stated to be 0.7-1.0µg/200µl of specimen (83)     
 
   Sample                         
   material                     1                       2, 3                       4                         5                        6                       7 
  
                                            
Figure 2.4  RNA extraction steps on the MagNA Pure Compact Instrument 
                    Figure adapted from the MagNA Pure Compact System Manual, Roche 2010 (84) 
 
2.2.4 RNA Amplification                                                                                    
RT-PCR was performed on RNA extracts using the Bio-Rad S1000™ Dual 48-block thermal 
cycler. The dual 48-block module enabled two PCR protocols to be run on the instrument at 
separate times. PCR protocols were programmed into the system using the semi-graphical 
display screen. The thermal gradient function was used to optimize annealing temperature for 
primers used in this study. The melting temperature (Tm) of the primers and gradient 
calculator was used to test 8 different temperatures starting from row A (highest temperature) 
to row H (lowest temperature). A maximum 24°C temperature range could be set from rows 
A to B. Protocols developed for the astrovirus and norovirus nRT-PCR assays are provided in 
Chapter 3.                                                                                                                                    
                                                                                                                CHAPTER 2:  Materials and methods 
 
50 
 
2.2.5  PCR Product Detection                                                                            
At the development stage of our PCR assays, the PCR products were detected by 
conventional gel electrophoresis: 1.5% (RT-PCR) and 2.0% (nPCR) agarose gels were 
stained with SYBR Safe DNA Gel Stain and visualised by UV transillumination. At the 
specimen testing stage, automated capillary electrophoresis was used due to the large 
numbers of specimens to be tested. With capillary electrophoresis 96 determinations could be 
performed in 1 run (8 x 12 row format) and test time was 8 minutes per row. The test 
principle was the same as conventional electrophoresis, except the gel was in capillary tubes 
(see 1.7.1.3). Twelve capillary tubes were in a test cartridge, corresponding to the 12 columns 
in the specimen tray. Before testing could commence, the QX DNA alignment marker was 
thawed to room temperature (20°C-25°C) and then loaded into the buffer tray. The separation 
method was selected as per manufacturers’ guidelines for PCR products <500bp: AM420 is 
recommended for DNA concentrations of 10-100ng/µL, and AL420 for <10ng/µL.  
 AM420 (RT-PCR) : Sample Injection Voltage (KV) -5mins 
            Sample Injection Time (s) – 10 mins 
            Separation Voltage (KV) – 5 mins 
                       Separation Time (s) – 420 
 
 
   AL420 (nPCR) : Sample Injection Voltage (KV) -8 mins 
         Sample Injection Time (s) – 20 mins 
         Separation Voltage (KV) – 5 mins 
                    Separation Time (s) – 420 
 
The stored QX DNA Marker in the instrument software was selected for analysis. Specimens 
in a 12 well strip were then loaded into the sample tray holder, sample information was 
entered into the software and the run commenced. The stored DNA marker was used by the 
instrument software to analyse the DNA product size and concentration.  Results were 
displayed as a gel image and electropherogram. 
                                                                                                                CHAPTER 2:  Materials and methods 
 
51 
 
2.2.6  DNA Purification                                                                                          
Prior to sequencing, the DNA PCR product was purified using the following protocol: 10µl 
of DNA product was mixed with 0.5µl of Exonuclease I and 1.0µl of Alkaline Phosphatase. 
The mixture was incubated at 37°C for 30 minutes. The reaction was stopped by heating the 
mixture at 85°C for 15 minutes.  
2.2.7  DNA Sequencing and Phylogenetic Analysis                                      
Purified DNA PCR product was sent for sequencing to the Australian Genome Research 
Facility (Sydney, Australia). The products were fluorescence-labelled by PCR amplification 
with appropriate forward and reverse primers and analysed by the AB3730x96-capillary 
sequencer. Sequence data of products from both reactions were viewed and edited using 
BioEdit version 7.1.3.0 (www.mbio.ncsu.edu/bioedit/bioedit.html). The sequences were then 
compared to reference sequences from the Genbank database at NCBI. Phylogenetic analysis 
was performed with the SeaView version 4 program                                                   
(http://pbil.univ-lyon1.fr/software/seaview), using ClustalW version 2 to create multiple 
sequences alignments and BioNJ to construct the phylogenetic tree (85).  
2.2.8  Statistical Analysis                                                                             
MedCalc version 12.2.1 (MedCalc Software, Mariakerke, Belgium) was used to determine 
sensitivity, specificity and 95% confidence intervals of the ELISA tests compared to the RT-
PCR and nRT-PCR assays. Stata 11 (Statacorp, College Station, Texas, USA) was used to 
estimate test comparisons if all specimens were tested by both ELISA and nRT-PCR using 
inverse probability weighting. 
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3.1  INTRODUCTION 
The aim of this chapter was to develop reliable, sensitive reverse transcription-polymerase 
chain reaction (RT-PCR) based assays that could be performed in diagnostic laboratories for 
the detection of astroviruses and noroviruses in stool specimens. The PCR assays developed 
should be able to detect all classic astrovirus capsid genotypes: HAstV- 1 to HAstV-8 and all 
norovirus GI and GII capsid genotypes.  The PCR primers were directed against the specific 
ORF2 regions of the astrovirus and norovirus genomes so that capsid genotypes can be 
determined from sequenced PCR products.                                                                                                     
The astrovirus RT-PCR assay we developed was adapted from published methods for 
astrovirus detection in stool specimens by Noel et al (13) and Resque et al (6).  These 
methods used the primer pair MON269/ MON270 to encode a 449bp region of the ORF2 
viral capsid gene and sequencing of PCR products from this area of the genome identified all 
eight classic astrovirus genotypes.  The norovirus GI and GII RT-PCR assays we developed 
were adapted from published methods by Yan et al. (72), Kojima et al.(70) and Kageyama et 
al (82). These methods used the primers pairs G1SKF/G1SKR and COG2F/G2SKR to 
encode 330bp and 387 bp regions of the ORF1/ORF2 junction (region C) to identify capsid 
genotypes. In the development of the molecular assays, reactions conditions (temperature 
profile) were optimised to suit the nature of our template; stool RNA extracts. A commercial 
system was used for RT-PCR (section 2.1.4.1) and reaction conditions were optimised by 
varying RT temperature/time, annealing temperature/time and cycle number. Methodology 
was developed to check for the presence of inhibitors to RT-PCR in the stool RNA extracts. 
To increase the sensitivity of astrovirus and norovirus detection we developed second round 
nested PCR assays (nPCR) based on the first round RT-PCR assays. Single primer pairs, 
targeting the first round RT-PCR products, were designed to give an astrovirus 329 bp 
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product, norovirus GI 150bp product and GII 242bp product.  Using a combination of 
published methods (14, 45, 86) and a commercial PCR system (section 2.1.4.2), conditions 
were optimised by varying annealing temperature/time and cycle number. The developed 
nested RT-PCR assays were checked for sensitivity, specificity and cross reaction to other 
RNA viruses commonly found in stools. 
  
3.2 FIRST ROUND REVERSE   
     TRANSCRIPTION-PCR (RT-PCR) 
 
3.2.1  METHODS   
3.2.1.1  Optimisation of First Round RT-PCR Conditions                                                       
The commercial system: Superscript
®
 III One-Step RT-PCR with Platinum
®
 Taq DNA 
Polymerase was used for the reaction. As system components were already optimised, 
optimal conditions in this assay were achieved by varying temperature cycling conditions. 
Optimal Reverse transcription (RT) temperatures and times were determined by testing 
various temperatures ranging from 45-55°C at different times from 30-60 min. Optimal PCR 
amplification conditions were determined by varying annealing temperature and time, and 
cycle number. All primers were used at a final concentration of 0.5µM. 
3.2.1.2  First Round RT-PCR Amplification and Analysis                                                                      
Preparation of PCR reaction Mix                                                                                           
Preparation of the PCR reaction Mix was done in the pre-PCR area (PCR area 1). The 
reaction mix for each test consisted of 12.5 µl of 2X Reaction Mix, 1.25µl of each primer 
(10µM) and 1.0µl of Superscript III RT/Platinum Taq Mix.                                                    
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Addition of RNA template                                                                                                                 
RNA extracts from astrovirus ELISA positive and negative stool specimens were used to 
develop the assay. A negative extraction control (sterile 0.45% saline only) was also 
included. Addition of template was performed in PCR area 2. The RNA templates, stored at 
4-8°C, were briefly centrifuged and 9µl was added to the reaction mix tube. Final reaction 
volume was 25µl.  
Amplification                                                                                                                                          
The tubes with PCR mix were briefly centrifuged in PCR area 3 and placed in the Bio-Rad 
S1000™ dual block thermal cycler for RNA amplification. The initial RT-PCR assays 
consisted of: reverse transcription at 55°C for 30 min., then PCR with denaturation at 94°C 
for 5 min, followed by 40 cycles of amplification (94°C for 30 sec, 50°C for 1 min, and 68°C 
for 1 min). Final extension was 68°C for 10 min with 4°C hold-up. 
Detection of PCR products                                                                                                                       
The PCR products were detected by conventional gel electrophoresis using a 1.5% agarose 
gel (2.1.5.1.3). The gel was run at 150V for 20 min. PCR products were visualised by UV 
transillumination, the gel results were photographed and stored in a gel documentation 
system.   
 
 
 
 
 
                                                CHAPTER 3:   Development of astrovirus and norovirus nRT-PCR assays 
56 
 
3.2.2  ASTROVIRUS FIRST ROUND RT-PCR RESULTS                                                                                          
3.2.2.1  Optimisation of First Round RT-PCR  Conditions                                                  
3.2.2.1.1  Reverse Transcription                                                                                                                                                
Initial testing was performed using an RT temperature of 55°C for 30 min. Using the initial 
RT conditions: 55°C for 30 min and new RT conditions: 45°C for 60 min we tested known 
astrovirus RT-PCR positive specimens to optimise RT conditions. Serial 10-fold dilutions of 
positive RNA extracts were tested under both conditions. Astrovirus ELISA positive stools 
that were negative in the initial RT-PCR assay were also tested.  The new RT conditions of 
42°C for 60 min were found to slightly improve RNA detection, compared to the initial RT 
conditions: Figure 3.1 shows a stronger 449bp target band at 10
-7
 dilution of the positive 
RNA extract (Figure 3.1B) and a 449 bp target band in the ELISA positive specimen (S) that 
was negative under initial RT conditions (Figure 3.1A).   
                                
                         
Figure 3.1  Astrovirus first round RT-PCR showing (A) RT conditions of 55°C for 30 min and (B) 
45°C for 1hr. The amplified products were run on a 1.5% agarose gel and the target band size was 
449bp. Positive RNA extract dilution products: 10
-3
, 10
-5
, 10
-7 
are shown . S is RNA extract from an 
ELISA positive stool. NSC is the negative RNA extraction control (saline). NRC is the no  
RNA control (MilliQ water used for dilutions). M is the 100bp bench-top PCR marker.         
 NRC     NSC        S        10-7       10-5       10-3        M  
◄449bp 
B 
      A ◄449bp
p 
NRC      NSC        S        10
-7
        10
-5
       10
-3
        M   
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3.2.2.1.2  PCR Amplification                                                                   
Annealing Temperature and Time                                                                                                   
Initial testing was performed using an annealing temperature (Ta) of 50°C for 30 sec. Using 
the initial conditions: 50°C for 30 sec and  new conditions: 50°C for 1 min we tested known 
astrovirus RT-PCR positive specimens to optimise RT conditions. Serial 10-fold dilutions of 
positive RNA extracts were tested under both conditions. The new annealing time of 1 min 
were found to enhance RNA detection, compared to the initial time of 30 sec.: Figure 3.2 
shows a stronger 449bp target band at both 10
-5
 and 10
-6
 dilutions of the positive RNA extract 
(Figure 3.2B) compared to the bands for 30 sec (Figure 3.2A). 
                         
                         
 
Figure 3.2  Astrovirus first round RT-PCR showing (A) annealing conditions of 50°C for 30 sec and 
(B) 50°C for 1min. The amplified products were run on a 1.5% agarose gel and the target band size 
was 449bp. Positive RNA extract dilution products: 10
-5
, 10
-6
, 10
-7 
are shown. NRC is the no RNA 
control (MilliQ water used for dilutions). Lane M is the 100bp bench-top PCR marker. 
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Cycle Number                                                                                                                       
Initial testing was performed using 40 cycles of amplification. Following optimisation of RT 
conditions and PCR annealing temperature and time, the cycle number was kept at 40. 
3.2.2.1.3  First Round RT-PCR Assay Conditions                                                                      
To summarise the optimisation of RT and PCR amplification, the astrovirus first round     
RT-PCR assay conditions used in this research are shown below in Table 3.1  
 
             Table 3.1 Astrovirus first round RT-PCR amplification conditions 
Program  
Code 
Steps Temperature 
(°C) 
Time Number of 
cycles 
AST3 Reverse Transcription 45 1 hr 1 
 Initial Denaturation 94 5 min 1 
 Denaturation 
Annealing 
Extension 
94 
50 
68 
30 sec 
1 min 
1 min 
  
40 
 Final extension 68 10 min 1 
 Hold 4 ∞ - 
 
3.2.3  NOROVIRUS FIRST ROUND GI RT-PCR AND GII RT-PCR        
          RESULTS 
  
3.2.3.1  Optimisation of First Round RT-PCR Amplification Conditions                                     
With the optimisation of astrovirus RT-PCR conditions, the same RT conditions of 45°C for 
1 hour were used for the norovirus RT-PCR assays. In PCR amplification, cycling conditions 
for annealing temperatures/times and cycle numbers were optimised. Other PCR 
amplifications conditions remained the same (see section 3.2.2.1.3).   
3.2.3.1.1  Norovirus GI PCR and GII PCR Amplification                    
Annealing Temperature                                                                                                         
The annealing temperature was determined using a thermal gradient. Serial 10-fold dilutions 
of positive RNA extracts were used for the reaction. Dilutions ranging from of 10
-3
 to 10
-5
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were tested over an eight temperature range (48.5°C-55.0°C). Figure 3.3 shows the GI 10
-4
 
dilution with slightly stronger 330bp target bands at the lower temperatures from 48.5°C to 
51.1°C compared to 55°C (Figure 3.3A) and the GII 10
-4
 dilution with stronger 387bp target 
bands between 48.5°C and 51.1°C (Figure 3.3B). The annealing temperature was set at 51°C 
for both the norovirus GI RT-PCR and GII RT-PCR. 
                      
                                                                                                                                               
                         
  
                       
 
Figure 3.3  Norovirus first round RT-PCR assays using an annealing temperature thermal gradient 
(A) GI RT-PCR with a 330bp target band size and (B) GII RT-PCR with a 387bp target band size. 
The amplified products were run on a 1.5% agarose gel. The 8 temperature thermal gradient was: 
48.5°C, 49.1°C, 50.0°C, 51.1°C, 52.6°C, 53.8°C, 54.5°C and 55°C in lanes 1-8 respectively. M is the 
100bp bench-top PCR marker.                                                                                              
 
Annealing Time                                                                                                                           
Optimal annealing times were determined with serial 10-fold dilutions of positive RNA 
extracts, ranging from 10
-3
 to 10
-6
, tested at annealing times of 30 sec and 45 sec. Figure 3.4 
shows stronger GI 330bp target bands at 10
-3
 to 10
-5
  dilutions with 45 sec (Figure 3.4B) 
compared to 30 sec (Figure 3.4A). GII 387bp target bands were also stronger at 45 sec 
(Figure 3.4D) with bands present at 10
-5
 dilution compared to 10
-4
 dilution at 30 sec     
(Figure 3.4C). The annealing times for both RT-PCR assays were set at 45 sec.                  
M                1       2      3       4       5       6       7       8                M 
◄387bp 
   B 
M                1       2       3        4       5       6       7       8                M 
   A 
 
◄330bp 
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Figure 3.4  Norovirus GI first round RT-PCR with annealing times of (A) 30 sec and (B) 45 sec, and 
Norovirus GII first round RT-PCR with annealing times of (C) 30 sec and (D) 45 sec. The amplified 
products were run on a 1.5% agarose gel and the target band size was 330 bp and 387 bp respectively. 
Positive RNA extract dilutions products: 10
-3
, 10
-4
, 10
-5
 and 10
-6
 are shown. NRC is the no RNA 
control (MilliQ water used for dilutions).M is the 100 bp bench-top marker. 
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Cycle Number                                                                                                                         
The optimal cycle number was determined with serial 10-fold dilutions of positive RNA 
extracts ranging from 10
-3
 to 10
-6
, tested at 40 and 45 cycles.  Figure 3.5 shows GI 330bp 
target bands and GII 387bp target bands seen in 10
-3
 to 10
-5
 dilutions as slightly stronger at 45 
cycles (Figure 3.5B and D) than at 40 cycles (Figure 3.5A and C). The cycle number was set 
at 45 for the norovirus first round GI RT-PCR assay and GII RT-PCR assay. 
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Figure 3.5  Norovirus GI first round RT-PCR with 40 cycles (A) and 45 cycles (B) and norovirus GII 
first round RT-PCR with 40 cycles (C) and 45 cycles (D). The amplified products were run on a 1.5% 
agarose gel and the target band sizes were 330bp and 387bp respectively. Positive RNA extract 
dilutions products: 10
-3
, 10
-4
, 10
-5
 and 10
-6
 are shown. NRC is the no RNA control (MilliQ water used 
for dilutions). M is the 100 bp bench-top marker. 
 
3.2.3.2.3  First Round RT-PCR Assay Conditions                                                                      
To summarise the optimisation of RT and PCR amplification, the norovirus GI first round 
RT-PCR and norovirus GII first round RT-PCR conditions used in this research are shown 
below in Table 3.2  
          Table 3.2 Norovirus first round GI RT-PCR and GII RT-PCR amplification conditions 
Program 
Code 
Steps Temperature 
 (°C) 
Time Number of  
cycles 
NOR12 Reverse 
Transcription 
   45        1 hr 1 
 Initial Denaturation    94     5 min 1 
 Denaturation 
Annealing 
Extension 
   94 
   51 
   68 
    30 sec 
    45 sec 
    1 min 
 
45 
 Final extension    68    10 min 1 
 Hold     4 ∞ - 
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3.2.4  First Round RT-PCR Assay Inhibition                                                                      
RNA extracts from first round RT-PCR negative samples were tested for inhibition by 
spiking the test sample volume of 8µl with 1µl of positive control extract, diluted 10 times 
less than the working dilution (9µl total volume). The positive control extract was tested at 
the working dilution. The extracts were tested in the first round RT-PCR assays and if the test 
extract target bands were weaker than the positive control extract target band, inhibitors were 
present in the RNA extract. Inhibitory RNA extracts were diluted 1:2 with milliQ water and 
rerun in the RT-PCR assay. Testing for inhibitors was repeated on the 1:2 dilutions to check 
for clearance of inhibition. RNA extracts that remained inhibitory were re-extracted, with the 
10% stool suspensions diluted 1:2 in sterile 0.45% saline (5% stool suspension). Figure 3.6A 
shows 7 RNA extracts from clinical specimens tested by astrovirus RT-PCR (lanes 3-9): 
three specimens showing complete inhibition (lanes 3, 8 and 9) with no target band of 449bp 
and three RNA extracts showed partial inhibition with weak target bands (lanes 4,6,and 7). 
Figure 3.6B shows the six inhibitory RNA extracts retested at 1:2 dilution (lanes 3-8) and the 
1:2 dilutions retested for inhibition (lanes 9-14). Inhibition was eliminated in four samples 
(lanes 10-13) and reduced in two samples (lanes 9 and 14). Specimens did not need to be re-
extracted. The retested 1:2 dilutions showed no specific 449bp target bands in the astrovirus 
RT-PCR (lanes 3-8). These results show that inhibitory substances may be present in stool 
specimens and their effect may be reduced by dilution. 
 
 
                                                CHAPTER 3:   Development of astrovirus and norovirus nRT-PCR assays 
64 
 
                     
     
 
 
 
Figure 3.6  Inhibition test in first round astrovirus RT-PCR (A) Inhibition test on seven specimen 
RNA extracts (lanes 3-9). Positive RNA extract is in lanes 11 and 12. (B) The six inhibitory RNA 
extracts retested at 1:2 dilution (lanes 3-8) and the 1:2 dilutions retested for inhibition (lanes 9-14). 
Positive RNA extract is in lanes 16 and 17. Lanes 1 are the no RNA control (MilliQ water used for 
dilutions). M is the 100bp bench-top PCR marker. The amplified products were run on a 1.5% agarose 
gel. 
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3.3   SECOND ROUND NESTED PCR   
       (nPCR) 
 
3.3.1  METHODS 
3.3.1.1  Optimisation of Second Round nPCR Conditions                                                       
The commercial system: AmpliTaq Gold
®
 PCR Master Mix was used for the reaction. As the 
components are already optimised, optimal conditions in this assay were achieved by varying 
temperature cycling conditions. Optimal PCR amplification was determined by varying 
annealing temperature and time, and cycle number. Primers were used at a concentration of 
0.5µM. 
3.3.1.2  Second Round nPCR Amplification and Analysis                                                               
Positive cDNA product from the first round RT-PCR assay was used to develop the second 
round nPCR assay. cDNA product from the negative extraction control (sterile 0.45% saline) 
was also included. Amplification and analysis for second round nPCR was performed in PCR 
areas 1-3 as in the first round RT-PCR assays. The reaction mix for each test consisted of 
12.5 µl of 2X Reaction Mix and 1.25µl of each primer (10µM). Addition of 10µl of cDNA 
template was added to the reaction mix tube. Final reaction volume was 25µl. DNA 
Amplification was performed using the Bio-Rad S1000™ dual block thermal cycler. The 
initial nPCR assay consisted of denaturation at 95°C for 10 min, followed by 40 cycles of 
amplification (94°C for 30 sec, 55°C for 40 sec, and 72°C for 1 min). Final extension was 
72°C for 10 min with 10°C hold-up. The PCR products were detected by conventional gel 
electrophoresis and visualised by UV transillumination as in the first round RT-PCR assay, 
but using a 2.0% agarose gel (section 2.1.5.1.3). The higher agarose concentration was used 
to provide distinct target bands and enhance detection of weak PCR products. 
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3.3.2.  ASTROVIRUS SECOND ROUND nPCR RESULTS         
3.3.2.1  Optimisation of Second Round nPCR Amplification Conditions 
3.3.2.1.1  nPCR Amplification                                                                   
Annealing Temperature and Time                                                                                                
The annealing temperature was determined using a thermal gradient. Serial 100-fold dilutions 
of positive cDNA product from the first round RT-PCR assay were used for the reaction. 
cDNA product dilutions ranging from of 10
-8
 to 10
-12
 (final RNA extract dilution) were tested 
over a eight temperature range (51°C-59°C). Figure 3.7 shows the 10
-10
 dilution with distinct 
329bp target bands over the temperature range and stronger bands between 53.2°C -56.8°C. 
The optimum annealing temperature was set at 55°C for the second round nPCR assay with 
annealing time at 40 sec. 
                     
 
Figure 3.7  Astrovirus second round nPCR assay using an annealing temperature thermal gradient. 
The amplified products were run on a 2.0% agarose gel and the target band size was 329bp. The eight 
temperature thermal gradient range was: 51°C, 52.1°C, 53.2°C, 54.4°C, 55.6°C, 56.8°C, 57.9°C and 
59°C in lanes 1-8 respectively. M is the 100bp bench-top PCR marker.  
 
 
Cycle number:  Initial testing was performed using 40 cycles. Using the above annealing 
temperature and time, serial 10-fold dilutions of positive cDNA product from 10
-12
 to 10
-15
 
(final RNA extract dilution) were tested at 40 and 45 cycles in the assay. Stronger 329bp 
target bands were seen at 40 cycles compared to 45 cycles (Fig. 3.8). Product detection was 
◄329bp 
M              1       2       3       4       5       6       7      8                M 
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not increased at 45 cycles and more primer-dimer was formed. Optimal cycle number was set 
at 40 cycles.                                                                                                       
        
 
Figure 3.8  Astrovirus second round nPCR assay at (A) 40 cycles and (B) 45 cycles with positive 
cDNA product diluted from 10
-12
 to 10
-15
. The amplified products were run on a 2.0% agarose gel and 
the target band size was 329bp. NDC is the no DNA control (MilliQ water used for dilutions). M is 
the 100bp bench-top PCR marker.  
 
3.3.2.1.2  Second Round nPCR Assay Conditions                                                                           
To summarise the optimisation of PCR amplification, the astrovirus second round nPCR 
assay conditions used in this research are shown below in Table 3.3 
               Table 3.3 Astrovirus second round nPCR amplification conditions 
Program  
Code 
Steps Temperature 
(°C) 
Time Number of 
cycles 
ASTN2 Initial Denaturation 95 10 min 1 
 Denaturation 
Annealing 
Extension 
94 
55 
72 
30 sec 
40 sec 
1 min 
 
40 
 Final extension 72 10 min 1 
 Hold 10 ∞ - 
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3.3.3.  NOROVIRUS SECOND ROUND GI AND GII nPCR RESULTS 
3.3.3.1  Optimisation of Second Round nPCR Amplification Conditions  
3.3.3.1.1  nPCR Amplification                                                                   
Annealing Temperature and Time                                                                                                
The annealing temperature was determined using a thermal gradient. Serial 10-fold dilutions 
of positive cDNA product from the first round RT-PCR assays were used for the reaction. 
cDNA product dilutions ranging from of 10
-11
 to 10
-16
 (final RNA extract dilution) were 
tested over an 8°C temperature range. GI was tested from 51°C-60°C and Figure 3.9 shows 
the GI 10
-15
 dilution with slightly stronger 150bp target bands at 51°C compared to 60°C 
(Figure 3.9A). GII was then tested at a lower temperature range from 49.9°C to 58.8°C to 
improve band intensity  difference, however, Figure 3.9B shows the GII 10
-14
 dilution with 
only slightly stronger 242bp target bands at 49.9°C compared to and 58.8°C. The optimum 
annealing temperature was set at a mid-point temperature of 55°C for both the norovirus 
second round GI nPCR and GII nPCR, with annealing time at 40 sec.  
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Figure 3.9  Norovirus second round nPCR assays using an annealing temperature thermal gradient 
(A) GI nPCR with a 150bp target band size and (B) GII nPCR with a 242bp target band size. The 
amplified products were run on a 2% agarose gel. The 8 temperature thermal gradient for NoV GI 
was: 51.0°C, 51.9°C, 53.1°C, 54.6°C, 56.6°C, 58.3°C, 59.4°C,60.0°C and for NoV GII:  49.9°C, 
50.9°C, 52.1°C, 53.5°C, 55.0°C, 56.4°C, 57.7°C,58.8.0°C in lanes 1-8 respectively. M is the 100bp 
bench-top PCR marker.                                                                                              
 
 
 Cycle number:  The optimum cycle number was determined with serial 10-fold dilutions of 
positive GI and GII cDNA products ranging from 10
-14
 to 10
-17
, tested at 40 and 45 cycles.  
Figure 3.10 shows GI 150bp target bands seen in 10
-15
 and 10
-16
 dilutions with similar 
intensity at 40 cycles (Figure 3.10A) and 45 cycles (Figure 3.10B). Likewise the GII 242bp 
target bands seen in 10
-14
 to 10
-16
 dilutions have similar intensity at 40 cycles (Figure 3.10C) 
and 45 cycles (Figure 3.10D). More primer-dimer formation is evident in 45 cycles, 
compared to 40 cycles for both PCR assays. The cycle number was set at 40 for both the 
norovirus second round GI nPCR and norovirus second round GII nPCR. 
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Figure 3.10  Norovirus GI second round nPCR with 40 cycles (A) and 45 cycles (B) and Norovirus 
GII second round nPCR with 40 cycles (C) and 45 cycles (D). The amplified products were run on a 
2.0% agarose gel and the target band sizes were 150bp and 242bp respectively. Positive cDNA 
product dilutions for GI: 10
-15
, 10
-16
, 10
-17
 and GII:  10
-14
, 10
-15
, 10
-16
 are shown. NDC is the no DNA 
control (MilliQ water used for dilutions). M is the 100 bp bench-top marker. 
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3.3.3.1.2  Second Round nPCR Assay Conditions                                                                      
To summarise the optimisation of PCR amplification, the norovirus second round GI nPCR 
and GII nPCR conditions used in this research are shown below in Table 3.4  
 
            Table 3.4  Norovirus second round GI nPCR and GII nPCR amplification conditions 
Program 
Code 
Steps Temperature 
(°C) 
Time Number of 
cycles 
NNOR Initial 
Denaturation 
95 10 min 1 
 Denaturation 94 30 sec  
 Annealing 55 40 sec 40 
 Extension 72 1 min  
 Final extension 72 10 min 1 
 Hold 10 ∞ - 
               
 
3.4  VALIDATION OF THE NESTED  
       RT-PCR ASSAYS              
 
3.4.1  SENSITIVITY OF THE NESTED RT-PCR (nRT-PCR) ASSAYS 
3.4.1.1  Improved Sensitivity of the astrovirus nRT-PCR Assay                                        
To examine the sensitivity of the nRT-PCR assay, serial 10-fold dilutions of the astrovirus 
positive control RNA extract were prepared to the range of 10
-5
 – 10-7. These dilutions were 
tested in the first round RT-PCR. For the second round nPCR, further serial 10-fold dilutions 
of these cDNA products were prepared to the range of 10
-10
 to 10
-12
 (final RNA extract 
dilution). The second round nPCR, markedly increased the sensitivity of the assay by 100,000 
fold. In the first round RT-PCR, two target bands were detected in the 10
-6
 dilution and in the 
second round nPCR, two target bands were seen in the 10
-11
 dilution (Fig. 3.11). 
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Figure 3.11  Comparison of the sensitivity of the first round astrovirus RT-PCR (A): serial dilutions 
10
-5 
to 10
-7 
and second round astrovirus nPCR (B): serial dilutions 10
-10
 and 10
-12
. M is the 100bp 
bench-top PCR marker 
 
 
.  
 
3.4.1.2  Improved Sensitivity of the norovirus GI nRT-PCR Assay and                                
              GII nRT-PCR Assay                                                                             
To examine the sensitivity of the nRT-PCR assay, serial 10-fold dilutions of the norovirus 
positive control GI and GII RNA extracts were prepared to the range of 10
-3
 – 10-6. These 
dilutions were tested in the first round GI RT-PCR and GII RT-PCR. For the second round 
nPCR, further serial 10-fold dilutions of these cDNA products were prepared to the range of 
10
-14
 to 10
-17
 (final RNA extract dilution). The second round nPCR, markedly increased the 
sensitivity of the assays with similar results. In the first round GI RT-PCR and GII RT-PCR, 
two target bands were detected in the 10
-5
 dilutions (Fig. 3.12A and C) and in the second 
round GI nPCR and GII nPCR, two target bands were seen in the 10
-16
 dilutions (Fig. 3.12B 
and D).   
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Figure 3.12  Comparison of the sensitivity of the first round RT-PCR of norovirus GI (A) and GII 
(C): serial dilutions 10
-3 
to 10
-6 
and second round norovirus GI nPCR (B) and GII nPCR(D): serial 
dilutions 10
-14
 to 10
-17
. M is the 100bp bench-top PCR marker.  
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3.4.2   SPECIFICITY OF THE NESTED RT-PCR (nRT-PCR) ASSAYs 
3.4.2.1  Astrovirus nRT-PCR Assay 
3.4.2.1.1  Astrovirus Specificity                                                                               
To confirm the specificity of the astrovirus nRT-PCR assay for astrovirus RNA detection, 
positive PCR products were purified and sequenced as in 2.2.6 – 2.2.7. Nucleotide profiles 
and sequences were viewed in BioEdit (version 7.1.3.0), as shown in Figure 3.13A. 
Sequences were trimmed and then analysed using BLAST. The result of a sequence 
alignment of a first round RT-PCR product is shown in Figure 3.13B. The sequence showed a 
99% homology to a reference HAstV-1 genotype (JN887820).  
 
A. Nucleotide sequence profile 
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B.  Sequence alignment  
CHW19      33  TTGGAACGGTCGGGTCAAACACCAGTGGCACTACCGAGATTGAGGCGTGTATTCTCCTCA   
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAstV-1  4508  TTGGAACGGTCGGGTCAAACACCAGTGGCACTACCGAGATTGAGGCGTGTATTCTCCTCA   
 
CHW19      93  ACCCTGTCCTTGTTAAGGACGCTACTGGGAGCACTCAGTTTGGCCCTGTGCAGGCGCTAG   
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAstV-1  4568  ACCCTGTCCTTGTTAAGGACGCTACTGGGAGCACTCAGTTTGGCCCTGTGCAGGCGCTAG   
 
CHW19     153  GTGCTCAGTATTCCATGTGGAAACTGAAGTATCTGAATGTCAAACTGACTTCTATGGTTG   
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
HAstV-1  4628  GTGCTCAGTATTCCATGTGGAAACTGAAGTATCTGAATGTCAAACTGACTTCTATGGTTG   
 
CHW19     213  GTGCGTCTGCCGTCAATGGCACTGTCCTTAGAGTTTCACTTAACCCAACATCTACACCGT   
               |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||| 
HAstV-1  4688  GTGCGTCTGCCGTCAATGGCACTGTCCTTAGAGTTTCACTTAACCCTACATCTACACCGT   
 
CHW19     273  CATCCACTAGTTGGTCAGGGTTAGGTGCACGTAAGCACCTTGATGTTACAGTGGGCAAAA   
               |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
HAstV-1  4748  CATCCACTAGTTGGTCAGGGTTGGGTGCACGTAAGCACCTTGATGTTACAGTGGGCAAAA   
 
CHW19     334  ATGCAACATTCAAATTGAAACCCTCTGACCTCGGTGGGCCTAGAGATG  381 
                   |||||||||| ||||||||||||||||||||||||||||||||||||| 
HAstV-1  4808  ATGCAACATTTAAATTGAAACCCTCTGACCTCGGTGGGCCTAGAGATG  4855 
 
 
Figure 3.13  Nucleotide sequence of a HAstV-1 first round RT-PCR product from a clinical specimen 
(CHW19).  A. Nucleotide sequence profile and B. Nucleotide sequence as viewed with BioEdit. C. 
Trimmed sequence alignment with a HAstV-1 reference sequence (JN887820) using BLAST 
 
3.4.2.1.2  Assay Specificity                                                                                      
To examine the specificity of the astrovirus nRT-PCR assay, its performance with norovirus 
and enterovirus, two other RNA viruses commonly found in diarrheal specimens was tested. 
RNA extracts from 11 norovirus and 11 enterovirus stool samples were run in the nRT-PCR 
assay. No target bands were detected in both the first round RT-PCR and second round 
nPCR. Figure 3.14 shows five positive norovirus RNA extracts and figure 3.15 shows five 
positive enterovirus RNA extracts tested in the nRT-PCR assay. 
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Figure 3.14  Astrovirus nRT-PCR result for five positive norovirus GII RNA extracts. cDNA 
products from second round nPCR are in lanes 2,4,6,8,10.  Positive cDNA products from norovirus 
GII RT-PCR are in lanes 3,5,7,9,and 11 (387bp)  Astrovirus positive cDNA product is in lane 13 
(329bp) . NSC is the negative RNA extraction control cDNA product (saline). M is the 100bp bench-
top PCR marker. Lanes 1 and 12 are blank. The amplified products were run on a 2.0% agarose gel. 
 
 
                  
 
Figure 3.15  Astrovirus nRT-PCR result for five positive enterovirus RNA extracts. cDNA products 
from second round nPCR are in lanes 1,3,5,7,9. Positive cDNA products from enterovirus RT-PCR 
are in lanes 2,4,6,8,and 10 (193bp)  Astrovirus positive cDNA product is in lane 12 (329bp). NSC is 
the negative RNA extraction control cDNA product (saline). M is the 100bp bench-top PCR marker. 
Lane 11 is blank. The amplified products were run on a 2.0% agarose gel. 
 
 
3.4.2.2  Norovirus nRT-PCR Assays 
3.4.2.2.1  Norovirus Specificity                                                                                 
To confirm the specificity of the norovirus nRT-PCR assays for norovirus GI and GII RNA 
detection, positive PCR products were purified and sequenced as in 2.2.6 – 2.2.7. Nucleotide 
profiles and sequences were viewed in BioEdit (version 7.1.3.0), as shown in Figure 3.16A 
and Figure 3.17A. Sequences were trimmed and then analysed using BLAST to confirm the 
identity of the products as NoV. The result of a sequence alignment of a norovirus GI first 
387bp► 
◄329bp 
M  NSC    1     2     3      4      5     6     7      8      9    10     11    12   13   M 
◄329bp 
 193bp► 
 M   NSC   1     2      3      4      5      6      7      8     9    10     11    12    M 
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round RT-PCR product from a clinical specimen (CHWN3) is shown in Figure 3.16B. The 
sequence showed a 100% homology to a reference NoV GI.4 genotype (GQ401129). The 
result of a sequence alignment of a norovirus GII first round RT-PCR product from a clinical 
specimen (NOR5) is shown in Figure 3.17B. The sequence showed a 99% homology to a 
reference NoV GII genotype (JX459615). 
 A.  NoV GI Nucleotide sequence profile 
 
B.  NoV GI Sequence alignment  
CHWN3      72   GACCCTATACCCATTGACCCTGTGGCTGGCTCCTCTACAGCACTTGCCACTGCAGGCCAA   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NoV GI.4   101  GACCCTATACCCATTGACCCTGTGGCTGGCTCCTCTACAGCACTTGCCACTGCAGGCCAA   
 
CHWN3      132  GTTAATTTGATTGATCCCTGGATAATCAATAATTTTGTGCAAGCCCCCCAGGGTGAATTC   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NoV GI.4   161  GTTAATTTGATTGATCCCTGGATAATCAATAATTTTGTGCAAGCCCCCCAGGGTGAATTC   
 
CHWN3      192  ACAATATCCCCAAACAATACCCCCGGTGATGTGCTTTTTGATTTGCAGTTAGGACCTCAT   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NoV GI.4   221  ACAATATCCCCAAACAATACCCCCGGTGATGTGCTTTTTGATTTGCAGTTAGGACCTCAT   
 
CHWN3      252  TTAAACCCTTTCCTCTCCCATCTCTCTCAGATGTACAATG  291 
                |||||||||||||||||||||||||||||||||||||||| 
NoV GI.4   281  TTAAACCCTTTCCTCTCCCATCTCTCTCAGATGTACAATG  320 
 
 
 
Figure 3.16  Nucleotide sequence of a NoV GI first round RT-PCR product from a clinical specimen 
(CHWN3)  A. Nucleotide sequence profile as viewed with BioEdit and B. Trimmed sequence 
alignment with a NoV GI.4  reference sequence (GQ401129) using BLAST 
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A.  NoV GII Nucleotide sequence profile 
 
B.  NoV GII Sequence alignment  
CHWN5      75   CCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGGCTCT   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
NoV GII.4  27   CCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGGCTTT   
 
CHWN5      135  GGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCAGGCCAACAAAATGTAATTGA   
                ||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| 
NoV GII.4  87   GGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGA   
 
CHWN5      195  CCCCTGGATTAGAAATAATTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAG   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NoV GII.4  147  CCCCTGGATTAGAAATAATTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAG   
 
CHWN5      255  AAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGCCCTGACCTGAATCCCTACCT   
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
NoV GII.4  207  AAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGCCCTGACCTGAATCCCTACCT   
 
CHWN5      315  ATCTCATTTGGCTAGAATGTA  335 
                |||||||||||| |||||||| 
NoV GII.4  267  ATCTCATTTGGCCAGAATGTA  287 
 
 
 
Figure 3.17  Nucleotide sequence of a NoV GII first round RT-PCR product from a clinical specimen 
(CHWN5)  A. Nucleotide sequence profile as viewed with BioEdit and B. Trimmed sequence 
alignment with a NoV GII.4  reference sequence (JX459615) using BLAST 
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3.4.2.2.2  Assay Specificity                                                                                      
To examine the specificity of the norovirus GI and GII  nRT-PCR assays, their performance 
with astrovirus and enterovirus, two other RNA viruses commonly found in diarrheal 
specimens were tested. RNA extracts from 11 astrovirus and 11 enterovirus stool samples 
were run in the nRT-PCR assays. No target bands were detected in both the first round RT-
PCR and second round nPCR for each assay. Figure 3.18 shows five positive astrovirus RNA 
extracts and five positive enterovirus RNA extracts tested in the NoV GI nRT-PCR assay. 
Figure 3.19 shows the same extracts tested in the GII nRT-PCR assay. 
             
 
              
          
Figure 3.18  Norovirus GI nRT-PCR result for five positive positive astrovirus RNA extracts (A) and 
five positive enterovirus RNA extracts (B). cDNA products from each second round nPCR are in 
lanes 2,4,6,8,10. Positive cDNA products from astrovirus RT-PCR (449bp) and enterovirus RT-PCR 
(193bp) are in lanes 3,5,7,9,and 11. Norovirus GI positive cDNA products are in lanes 12 (150bp). 
NSC is the negative RNA extraction control cDNA product (saline) for the GI nRT-PCR assay. M is 
the 100bp bench-top PCR marker. Lanes 1 are blank. The amplified products were run on a 2.0% 
agarose gel. 
 
 
 
    A 
◄150bp 
M   NSC   1       2      3      4      5      6      7      8       9    10      11    12    M 
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Figure 3.19  Norovirus  GII nRT-PCR result for five positive astrovirus RNA extracts (A) and five 
positive enterovirus RNA extracts (B). cDNA products from each second round nPCR are in lanes 
2,4,6,8,10.  Positive cDNA products from astrovirus RT-PCR (449bp) and enterovirus (193bp) are in 
lanes 3,5,7,9,and 11.  Norovirus GII positive cDNA products are in lanes 12 (242bp). NSC is the 
negative RNA extraction control cDNA product (saline). M is the 100bp bench-top PCR marker. 
Lanes 1 are blank. The amplified products were run on a 2.0% agarose gel. 
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 3.5  DISCUSSION 
The developed nested RT-PCR assays consisting of a first round RT-PCR and second round 
nested PCR appear to be sensitive, specific assays. The first round astrovirus RT-PCR  
detected positive PCR product to 10
-6
 dilution of a RNA extract and both the norovirus GI 
RT-PCR and GII RT-PCR detected product to 10
-5
 dilution. The development of the second 
round nPCR increased the sensitivity to a detection level of 10
-11
 dilution for astrovirus and 
10
-16
 for norovirus GI and GII. Sequences of positive PCR products were specific as they 
were identified as astrovirus or norovirus using BLAST and the nRT-PCR assays did not 
cross-react with two other common RNA viruses found in stools.                                                                                                                                               
The primer pair MON269/MON270 were chosen for the first round astrovirus RT-PCR as 
they are directed against a conserved region of the ORF2 virus capsid gene and have been 
used in many published studies to identify all eight classic astrovirus capsid genotypes (13, 
16, 86, 87). Some published studies have used the primer pair MON244/MON245 (7, 18) to 
the capsid gene, however, they may not be as universal for detection of all HAstV genotypes 
(13, 86). Primer pair MON340/MON348 to the polymerase gene (ORF1a) have also been 
used for genotyping, however, this area of the genome is not conserved and is usually used to 
detect recombinance (18, 44). The primer pairs G1SKF/G1SKR and COG2F/G2SKR were 
chosen for the first round norovirus GI RT-PCR and GII RT-PCR as they target the highly 
conserved ORF1/ORF2 junction region (region C). Published studies have shown they can 
detect a broad range of norovirus strains (50, 72, 88) compared to primers to the RdRp gene 
of ORF1 (region A) (70) and the 3’ end of ORF1 (region B)(89). The second round of nested 
PCR was developed to increase sensitivity of the RT-PCR assays as several studies have 
shown that RT-PCR alone may underestimate the prevalence of astrovirus infection (14, 45, 
86) and norovirus infection (14, 90). This increased sensitivity may be necessary for the 
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detection of low level, persistent astrovirus infection in immunocompromised patients in our 
study. The developed nRT-PCR assays will be used to test for the presence of astrovirus and 
norovirus RNA in stool specimens over the 2 year study period and positive PCR products 
will be genotyped. Specimen testing and results are in chapter 4. 
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4.1  INTRODUCTION 
The aim of this chapter was to determine the prevalence of astrovirus and norovirus infection 
in a paediatric setting, The Children’s Hospital at Westmead. Faecal specimens were tested 
over a two year period from January 2009 to December 2010 from children presenting with 
diarrheal symptoms. Faecal specimens were tested for astrovirus and norovirus antigens using 
commercial ELISA kits. Antigen positive specimens were then tested for viral RNA using 
our developed molecular assays: astrovirus nRT-PCR assay, norovirus GI nRT-PCR assay 
and norovirus GII nRT-PCR assay. Positive PCR products were sequenced and genotypes 
determined. Phylogenetic analysis was performed on sequenced products. Performance of the 
commercial ELISA tests compared to the developed molecular assays was determined by 
testing ELISA negative specimens in the nRT-PCR assays. The astrovirus and norovirus 
ELISA sensitivities and specificities compared to the nRT-PCR assays were estimated and 
used to determine the prevalence of astrovirus and norovirus infection at The Children’s 
Hospital at Westmead. Analysis of viral infection rates, seasonal distributions, age 
distributions, patient types, nosocomial infections, and viral genotypes was performed. 
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4.2  ASTROVIRUS RESULTS 
4.2.1   ELISA versus nRT-PCR                                                                         
Over the two year study period, 5052 stool specimens were tested by astrovirus ELISA. From 
the 5052 stool specimens tested, 24 were positive for astrovirus (0.5%). The 24 ELISA 
positive specimens all tested positive by PCR: 21 were positive by RT-PCR (87.5%), and 3 
more were positive by nRT-PCR (12.5%). To compare the sensitivity and specificity of the 
ELISA test to the nRT-PCR assay, 150 ELISA negative specimens were tested by PCR. 
Negative specimens were selected from each month of the two year period, with a minimum 
of six and a maximum of nine specimens tested per month. From these ELISA negative 
specimens, 7 were positive: 5 positive by RT-PCR (71.4%), and 2 more positive by nRT-
PCR (28.6%). All of the PCR negative specimens were tested for inhibition: 17 specimens 
showed some inhibition.  Inhibition was eliminated in 16 specimens with 1:2 dilution of the 
RNA extracts, and one specimen required dilution to a 5% suspension and re-extraction. 
None of the 17 inhibitory samples were positive when retested in the nRT-PCR assay.                                               
Table 4.1 summarises the detection methods for the 31 positive astrovirus stool specimens.                                                                                                                             
Compared to the single round RT-PCR (Table 4.1A), the ELISA assay gave a sensitivity of 
80.8% (95% CI= 60.7-93.5%) and specificity of 98.0% (95% CI= 94.1-99.6%). The positive 
predictive value (PPV) was 87.5% (95%CI= 67.6-97.3%) and negative predictive value 
(NPV) 96.7% (95%CI= 92.4-98.9%). When compared to nRT-PCR as the reference standard 
(Table 4.1B) the ELISA sensitivity was 77.4% (95% CI= 58.9-90.4%) and specificity 100% 
(95% CI= 97.5-100.0%). The PPV was 100.0% (95%CI= 85.7-100.0%) and NPV 95.3% 
(95%CI= 90.6-98.1%). The number of astrovirus positive specimens if all study specimens 
had been tested by both ELISA and nRT-PCR was estimated in Strata 11 (Stratacorp, College 
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Station, Texas, USA) using inverse probability weighing. The estimated incidence of 
astrovirus was calculated to be 5.1% (95% CI= 4.53-5.77%), 260 of 5052 specimens. 
 
 
                             
 
    
 
                             
 
 
Stool specimens from an external source were also tested in the nRT-PCR assay. A total of 
four specimens were tested from the Microbiology Department, Centre for Infectious 
Diseases and Microbiology Laboratory Services (CIDMLS), Institute of Clinical Pathology 
and Medical Research (ICPMR), Westmead Hospital. These specimens had not been tested 
by astrovirus ELISA at Westmead Hospital, but screening for astrovirus RNA had been 
performed using the commercial multiplex real-time assay, Easy Screen™ Enteric Viral 
Detection Kit from Genetic Signatures (Sydney, Australia). Using our developed astrovirus 
nRT-PCR assay, astrovirus RNA was detected in two specimens in the first round RT-PCR, 
 
    RT-PCR 
      Result 
ELISA Result 
 
  No. of 
  specimens 
Positive Negative  
Positive 21 5 26 
Negative 3 145 148 
No. of specimens 24 150 174 
 
    nRT-PCR 
       Result 
ELISA Result 
 
  No. of 
  specimens 
Positive Negative  
Positive 24 7 31 
Negative 0 143 143 
No. of specimens 24 150 174 
Table 4.1  Comparison of astrovirus ELISA to (A) RT-PCR and (B) nRT-PCR 
 
 
   A 
        B 
                           
B 
 
                           
B 
 
                           
B 
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and two specimens remained negative after the second round nPCR. These results correlated 
with the commercial PCR kit results from ICPMR.  
 
4.2.2  GENOTYPING AND PHYLOGENETIC ANALYSIS 
Positive RT-PCR and nRT-PCR products from 29 of 31 specimens were sequenced and 
genotypes determined. There was insufficient product in two samples for sequencing. 
HAstV-1 to 4 genotypes were identified: HAstV-1 in 23 specimens (79.3%), HAstV-2 in one 
specimen (3.4%), HAstV-3 in 3 specimens (10.3%) and HAstV-4 in 2 specimens (6.9%), 
(Table 4.2). The phylogenetic analysis revealed that HAstV-1 positive specimens were 
clustered into two distinct lineages: 14 specimens of HAstV-1a and 9 specimens of HAstV-
1d (Figure 4.1) The HAstV-1a cluster showed a nucleotide  identity of 96.3-100% between 
themselves and 96.0-100% to the GenBank reference strains of Oxford  L23513 (91), 
Singapore HM209087 (92), Colombia FJ165469 (93), and Russia JF929185. The HAstV-1d 
cluster showed an identity of 95.0-99.7 % between themselves and 96.2-99.7% to GenBank 
reference strains of Russia FJ004201, Italy JQ303025 (94), Beijing FJ755403 (95) and Korea 
JN887820 . The HAstV-2 specimen was of  lineage 2c and showed an identity of 93.9-99.1%  
to the GenBank reference strains of  India AB551371 and Oxford L13745 (96).  The three 
HAstV-3 specimens showed a 100%  identity  between themselves and 92.5-99.4% to the 
GenBank reference strains of India AB548404 and Oxford L38505 (13). The two HastV-4 
specimens were of lineage 4a and showed an identity of  98.8 -100% between themselves and 
95.6-99.7% to the GenBank reference strains of Colombia FJ165475 (93) and Oxford L38506 
(13).   Representative sequences from genotypes determined in this study were deposited into 
the GenBank database under accession numbers: KC137237-KC137249.      
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Table 4.2  Astrovirus genotypes – detection methods and patient types 
      HAstV TOTAL ELISA  RT-PCR nPCR PATIENT TYPE 
GENOTYPE NO. (%) RESULT NO. (%)   POS (%) POS (%) EC (%) I (%) N (%) 
1a 14 (45.2) POS  10 (71.4) 10 (71.4)         -   6 (60.0)  4 (40.0) - 
  NEG   4   (28.6)  3 (21.4)   1 (7.1)   1 (25.0)  3 (75.0)  
1d   9 (29.0) POS   7 (77.8)  6 (66.7)   1 (11.1)   2 (22.2)  5 (66.7)       - 
  NEG   2 (22.2)  1 (11.1)   1 (11.1)   1 (11.1)  1 (11.1) 
2c   1 (3.2) POS   1 (100.0)    1 (100.0) -   1(100.0) - - 
  NEG   0 (0.0) -     
3   3 (9.7) POS   3 (100.0)    3 (100.0) -   3(100.0) - - 
  NEG   0 (0.0) -     
4a   2 (6.4) POS   1 (50.0)  1 (50.0) -   2(100.0) - - 
  NEG   1 (50.0)  1 (50.0)     
not typed   2 (6.4) POS   2 (100.0) -   2 (100.0) -  2(100.0) - 
  NEG   0 (0.0) -     
TOTAL 31 (100.0) 26 (83.9)   5 (16.1) 16 (51.6) 14 (45.2) 1 (3.2) 
       
EC= Emergency  I= Immunosuppressed  N= Nosocomial 
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4.2.3  PATIENT DEMOGRAPHICS 
4.2.3.1  Astrovirus Distribution                                                                                             
Astrovirus was found in all months of the year, with seasonality unclear due to the low 
number of positive specimens (Figure 4.2). Of the 31 specimens positive for astrovirus there 
were more astroviruses detected in 2009: 18 positives compared to 13 in 2010. Astrovirus 
infection rates were higher in 2009 (0.8%) with three genotypes responsible for infections: 
HAstV-1a predominated from May-September causing 57.9% infection, whereas HAstV-1d 
was found from September to December with 31.6% infection and HAstV-3 caused 10.5% 
infection in December. The two HAstV untyped specimens were detected in August and 
December, 2009. Infection rates were lower in 2010 (0.5%) with the majority of infections 
occurring from May to August (76.9%) and four genotypes were responsible for infections. 
HAstV-1a was responsible for less infection with a rate of 38.5%, HAstV-1d at 30.8%, 
HAstV-2 and HAstV-3 each causing 7.6% infection, and HAstV-4a responsible for 15.4% 
infection.     
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4.2.3.2  Patient Types                                                                                                  
Analysis of patient types with astrovirus infection showed 16 positive specimens (51.6%) 
were from patients presenting to the Emergency Department, 14 (45.2%) from 
immunocompromised patients presenting to the Outpatient Clinics and one (3.2%) from 
nosocomial acquired infection (Table 4.2).                                                                                                        
All of the Emergency Department patients were clinically diagnosed with gastroenteritis on 
presentation at the hospital. From these patients, seven had HAstV-1a infections (43.8%) and 
three patients had HAstV-1d infections (18.8%). Genotypes HAstV-2c, HAstV-3 and HAstV-
4a were only found in Emergency patients. HAstV-2c was found in one patient (6.3%), 
HAstV-3 in three patients (18.8%) and HAstV-4a in two patients (12.5%). Three infected 
patients had recently travelled overseas: one HAstV-1a positive patient had been to Sudan, 
one HAstV-4a positive patient to Burma, and the one HAstV-2c patient to Afganistan.  
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Figure 4.2  Seasonal distribution of astrovirus from January 2009 to December 2010 
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There were two cases of co-infection with bacteria in Emergency patients: one patient was 
infected with HAstV-1a, Campylobacter sp. and Salmonella sp. and another patient with 
HAstV-4a and Campylobacter sp.                                                                                                      
In the immunocompromised patients, genotypes HAstV-1a and HAstV-1d were found: seven 
patients with HAstV-1a infection (50.0%) and five patients with HAstV-1d infection 
(35.7%). There were two HAstV specimens with insufficient PCR product for typing 
(14.3%). Of the immunocompromised patients, 25% were clinically assessed as having 
gastroenteritis and 75% as having diarrhoea or loose stools on presentation to the Outpatient 
clinics. There were two cases of co-infection with astrovirus and norovirus in 
immunocompromised patients with genotypes HAstV-1d and NoV GII.4.  The patient with 
nosocomal acquired infection was clinically diagnosed with gastroenteritis in the hospital 
ward and had genotype HAstV-1d.  
4.2.3.3. AGE DISTRIBUTION                                                                               
The age of children with astrovirus infection ranged from six months to 15 years and the 
median age was 1.75 years.  Incidence of infection was higher in children under five years of 
age (2.5%).  As shown in Figure 4.3A, the highest incidences were in the 6-12 month age 
group (1.1%) and the 1-2 year age group (1.0%). Figure 4.3B shows the age distribution of 
astrovirus genotypes. HAstV-1a was mainly found in children under six years of age. 
Genotype HAstV-1d was found up to the 11-15 year age group. The low numbers for 
genotypes HAstV-2c, HAstV-3 and HAstV-4a made age distribution unclear. No HAstV 
genotypes were found in the 0-6 month age group.                                                                                 
The ratio of infection in males and females was similar at 0.68% (19 out of 2807) and 0.58% 
(13 out of 2245), respectively. The HAstV-1a genogroup was predominant in males with a 
ratio of infection of 0.35% compared to 0.18% in females. The HAstV-1d ratio of infection 
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was slightly higher at 0.22% in females compared to 0.14% in males. HAstV genotypes 2c,3 
and 4a were found in males and one HAstV-3 genotype was found in a female patient.  
 
 Figure 4.3  Percentage positive specimens for (A) astrovirus per age group and (B ) astrovirus 
genotypes per age group 
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4.3  NOROVIRUS RESULTS 
4.3.1   ELISA versus nRT-PCR 
As in the astrovirus study, 5052 stool specimens were tested by norovirus ELISA, among 
which 331 were positive (6.6%) and 34 were equivocal for norovirus (0.7%). From the 331 
ELISA positive specimens, 327 were tested by nRT-PCR with four specimens insufficient for 
further testing. A total of 323 ELISA positive specimens tested positive by the molecular 
assays (Table 4.3). In the RT-PCR:  201 specimens were GII (62.2%), 4 were GI and GII 
(1.2%) and one GI (0.3%). In the second round nPCR, 117 more were positive: 116 GII 
(35.9%) and one both GI and GII (0.3%). There were four ELISA positive specimens that 
remained negative in the nRT-PCR assays. From the 34 ELISA equivocal specimens, 33 
were tested by PCR with one specimen insufficient for further testing. A total of 24 ELISA 
equivocal specimens were positive by PCR: 5 by GII RT-PCR (15.1%) and 19 more in the 
second round GII nPCR (57.6%). There were nine ELISA equivocal specimens that were 
negative in the nRT-PCR assays.                                                                                              
To compare the sensitivity and specificity of the ELISA test to the nRT-PCR assays, 72 
ELISA negative specimens were randomly selected for PCR testing: 36 from July-August, 
2009 and 36 from July-August, 2010. This number corresponded to the 36 positive ELISA 
specimens detected in each of the periods July-August 2009 and 2010. As well, 16 random 
ELISA negative specimens that had been previously tested by PCR from months outside 
these periods were also included. From these ELISA negative specimens, 23 were positive: 4 
by GII RT-PCR (17.4%), and 19 more by GII nRT-PCR (82.6%). None of the specimens 
were positive in the GI nRT-PCR assay. All of the PCR negative specimens were tested for 
inhibition: 10 specimens showed some inhibition. Inhibition was eliminated with 1:2 dilution 
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of the RNA extracts. When retested in the GI and GII nRT-PCR assays, eight specimens were 
positive in the GII second round nPCR. Compared to the single round RT-PCR (Table 4.3A) 
the ELISA assay gave a sensitivity of 98.1% (95% CI= 95.2-99.5%) and specificity of 41.0% 
(95% CI= 34.2-48.0%). The PPV was 63.0% (95%CI= 57.5-68.2%) and NPV 95.4% 
(95%CI= 88.8-98.8%). When compared to nRT-PCR as the reference standard (Table 4.3B) 
the ELISA sensitivity was 93.3% (95% CI= 90.2-95.7%) and specificity 94.2% (95% CI= 
85.8-98.4%).  The PPV was 98.8% (95%CI= 96.9-99.7%) and NPV 73.9% (95%CI= 63.4-
82.7%). As with astrovirus, the estimated norovirus incidence if all study specimens were 
tested by both ELISA and nRT-PCR was calculated to be 30.9% (95% CI= 29.63-32.19%), 
1564 of 5052 specimens.                                                                                                                       
                                                                                                                                                                                                                                             
 
 
                             
 
    
  
 
                             
                            
 
 
  
 
 
      RT-PCR 
      Result 
ELISA Result 
 
  No. of 
  specimens 
Positive Negative  
Positive 206 4 210 
Negative 121 84 205 
No. of specimens 327 88 415 
 
      nRT-PCR    
         Result 
ELISA Result 
 
  No. of 
  specimens 
Positive Negative  
Positive 323 23 346 
Negative 4 65 69 
No. of specimens 327 88 415 
Table 4.3  Comparison of norovirus ELISA to (A) RT-PCR and (B) nRT-PCR 
 
 
A 
  B 
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A total of five specimens were also tested from the Microbiology Department, CIDMLS, 
ICPMR, Westmead Hospital in the nRT-PCR assays. These specimens had been tested by 
norovirus ELISA at Westmead Hospital and screening for norovirus RNA had been 
performed, as with astrovirus, using the Easy Screen™ Enteric Viral Detection Kit from 
Genetic Signatures (Sydney, Australia). Using our developed GI and GII nRT-PCR assays, 
norovirus RNA was detected in all five specimens: three specimens in the first round GII RT-
PCR, and two specimens in the second round GII nPCR. No norovirus RNA was detected in 
the GI nRT-PCR assay. These results correlated with the results from ICPMR: GII RNA was 
detected in all five specimens that had tested negative by norovirus ELISA.                                                                                                                  
 
 
4.3.2  GENOTYPING AND PHYLOGENETIC ANALYSIS 
Positive RT-PCR and nRT-PCR products from 357 of 366 specimens were sequenced and 
genotypes determined (Table 4.4). There was insufficient product in nine samples from the 
GII nPCR for sequencing. Norovirus GI genotypes were confirmed in the six specimens 
detected by the nRT-PCR assay (1.6%): one specimen on its own and five in combination 
with norovirus GII. Norovirus GII genotypes were identified on their own in 351 specimens 
(95.9%).                                                                                                                       
Sequencing results revealed that the GI genotype for the specimen with positive GI product 
was GI.6 and the five specimens with both GI/GII products were: GI.1/GII.4, GI.2/GII.4, 
GI.4/GII.4 and GI.13/GII.4 and GI unidentified subtype/GII.4.  Phylogenetic analysis was 
performed comparing the six sequenced GI products to reference stains in Genbank (Figure 
4.4). The GI.1 genotype showed a 95.9% nucleotide identity to Genbank reference strain 
FJ383884. The GI.2 genotype showed a 96.0% identity to KC413404. The GI.4 genotype 
showed a 100% identity to GQ401129 and 93.2% to AB042808 (97). The GI.6 genotype 
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showed a 99.6% identity to JQ388274 and 92.7% to AJ277615 (98). The GI.13 genotype 
showed a 97.7% identity to EU363857 (50). The GI product unidentified subtype showed a 
94.1%  identity to AJ277617 (98).  
 
 
        NoV TOTAL ELISA  RT-PCR nPCR PATIENT TYPE 
  GENOTYPE NO. (%)  RESULT NO. (%)   POS (%) POS (%) EC (%) I (%) N (%) 
GI.1  1 (0.3) POS   1 (100.0)  1 (100.0) -   1 (100.0) -       - 
GII.4 2010  NEG   0 (0.0)         
GI.2  1 (0.3) POS   1 (100.0)  1 (100.0) -   1(100.0) - - 
GII.4 2008  NEG   0 (0.0) -     
GI.4  1 (0.3) POS   1 (100.0)  1 (100.0) -   1(100.0) - - 
GII.4 2006  NEG   0 (0.0) -     
GI.6  1 (0.3) POS   1 (100.0)  1 (100.0) -   1(100.0) - - 
  NEG   0 (0.0)       
GI (unsub) 1 (0.3) POS   1 (100.0) 1 (100.0) -   1 (100.0) - - 
GII.4 2008  NEG   0 (0.0)          
GI.13 1 (0.3)   POS   1 (100.0)         - 1 (100.0)   1 (100.0) - - 
GII.4 2008  NEG   0 (0.0)      
GII.2 3 (0.8) POS   2 (66.7)   2 (66.7) -   1 (50.0)  1 (50.0) - 
  EQUI   1 (33.3)   1 (33.3) -         - 1 (100.0) - 
  NEG   0 (0.0)         - - -        - - 
GII.3 65(17.5) POS  57 (87.7)  40 (61.5)   17 (26.2)  34 (59.6) 12 (21.1) 11 (19.3) 
  EQUI   2 (3.1)   2 (3.1) -   2 (100.0)        - - 
  NEG   6 (9.2)   1 (1.5)   5 (7.7)   4 (66.7)   2 (33.3) - 
GII.4 2006b 44 (12.0) POS   34 (77.3)  26 (59.2)   8 (18.2)  22 (64.7)   6 (17.6)   6 (17.6) 
  EQUI   2 (4.5)   1 (2.3)   1 (2.3)   1 (50.0)   1 (50.0) - 
  NEG   8 (18.2)   2 (4.5)   6 (13.6)   5 (62.5)   3 (37.5) - 
GII.4 2008 105(28.7 POS 98 (93.3)  69 (65.7) 29 (27.6)   63 (64.3) 17 (17.3) 18 (18.4) 
  EQUI   6 (5.7)   1 (0.9)   5 (4.8)   3 (50.0)       -   3 (50.0) 
  NEG   1 (1.0) -   1 (1.0)          - 1 (100.0) - 
GII.4 2010 95 (26.0) POS 78 (82.1)  35 (36.8) 43 (45.3) 54 (69.2) 20 (25.6)  4 (5.1) 
  EQUI 10 (10.4)          - 10 (10.4)   7 (70.0)    3 (30.0) - 
  NEG   7 (7.3)    1 (1.0)   6 (6.3)   4 (57.1)   3 (42.9) - 
GII.6 6 (1.6) POS   5 (83.3)    5 (83.3) -   5 (100.0)        - - 
  NEG   1 (16.7)    1 (16.7) -   1 (100.0)        - - 
GII.7 22 (6.0) POS 22 (100.0) 15 (68.2)   7(31.8) 12 (54.5) 10 (45.5)        - 
  NEG   0 (0.0) - - -        - - 
GII.12 9 (2.5) POS   8 (88.9)   7 (77.8%)   1 (11.1)   3 (37.5)   5 (62.5)        - 
  EQUI   1 (11.1)          -   1 (11.1) - 1 (100.0) - 
  NEG   0 (0.0) - - -        - - 
GII.13 2 (0.5) POS   2 (100.0)   2 (100.0) -   2 (100.0)        - - 
  NEG   0 (0.0) - - -        - - 
     GII 9 (2.5) POS   9 (100.0) -   9 (100.0)   2 (22.2) 4 (44.4) 3 (33.3) 
 not typed  NEG   0 (0.0)      
TOTAL 366 (100.0) 213 (58.2) 153 (41.8) 231 (63.1) 90 (24.6) 45 (12.3) 
EC= Emergency  I= Immunosuppressed  N= Nosocomial  unsub= unknown subtype 
 
   
Table 4.4  Norovirus genotypes – detection methods and patient types 
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Sequencing results for the specimens with GII products alone were: GII.2 in 3 specimens 
(0.8%), GII.3 in 65 specimens (18.5%), GII.4 in 244 specimens (69.5%), GII.6 in 6 
specimens (1.7%), GII.7 in 22 specimens (6.3%), GII.12 in 9 specimens (2.6%) and GII.13 in 
2 specimens (0.6%). Phylogenetic analysis was performed comparing sequenced GII products 
to reference strains in GenBank (Figure 4.5). The GII.2 genotypes showed a nucleotide 
identity of 97.0-100.0% between themselves and  95.7-99.2% to the Genbank reference 
strains of  Snow Mountain 2 U70059 (99) and Netherlands AB281089. The GII.3 genotypes 
were divided into two clusters, with one cluster showing an identity of 94.8-100.0% between 
themselves and 94.4-100.0% to Singapore JX480611, China JQ934817 and India EU921389 
(100). The other GII.3 cluster showed an identity of 97.3-100.0% between themselves and to 
GQ856467 (101), FJ595920 (102) and JX863464. The GII.4 genotypes were divided into 
three clusters: variant 2006b, variant 2008 and variant 2010. The 2006b variants showed the 
closest identity of 94.0-98.1% to the past 2002 epidemic strain, Farmington Hills AY502023. 
The 2006b variants were divided into two clusters, with one cluster of showing an identity of 
95.2-99.2% between themselves and 95.6-99.5% to GQ379151 (9) and JQ613525. The larger 
2006b cluster showed an identity of 96.5-99.6% between themselves and 97.6-100.0% to 
JQ750995 (103), EF126965 (104), HQ003268, JX459615, GQ379151 and JQ613525. The 
2008 variants showed an identity of 94.8-99.2% between themselves and had a closer identity 
of 95.0-98.9% to the 2006b epidemic strain, Den Haag EF126965 compared to 94.0-98.1% to 
the 2002 Farmington Hills strain, AY 502023. They were divided into two clusters, with one 
smaller cluster showing a closer identity of 98.8-99.2% to the Mannheim strain, GQ303445 
(105) and a 99.6-100.0% identity to JQ613529 and HM748973 (106). The larger 2008 variant 
cluster showed a 98.5-99.6% identity to the Apeldorn strain, AB445395 and was divided into 
four smaller clusters showing an identity of 98.5-100.0% to JQ613556, 99.2-100.0% to 
JQ613542, 99.1-100.0% to JQ613527 and 99.6-100.0% to JQ613539.  The 2010 variants 
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showed a close identity of 98.8-100.0% between themselves and a closer identity of 98-99% 
to the 2008 Apeldorn strain, AB445395, compared to 96.5-97.7% to the 2002 Farmington 
Hills strain, AY 502023. Amongst themselves they showed a 98.4-99.2%  identity to the New 
Orleans epidemic strains from 2010: JF697259 (107), JF692258 (107) and HQ230937.                                                                                                                              
The GII.6 genotypes showed a 94.0-99.6% identity between themselves and were divided 
into two clusters. One cluster showed a 98.4-99.0% identity to GU909657 and the other 
cluster a 97.2-99.6% identity to AB539143. The GII.7 genotypes showed a 96.9-100.0% 
identity between themselves and were divided into two clusters that were closest in identity to 
the JQ751043 strain (103). One cluster showed a 98.1-99.2% identity amongst themselves 
and a 98.8-100.0% identity to JQ751043. The second cluster was divided into two smaller 
clusters: one showed a 99.2-100.0% identity between themselves and a 95.8-98.8% identity 
to JQ751043 and 94.9-95.3% to AJ277608 (98). The other small cluster showed a 100% 
identity to themselves and a 96.9% identity to JQ751043 and 95.9%  to AF414409 (108). The 
6 GII.12 genotypes showed a 99.2-99.6% identity between themselves and a 99.6-100.0% 
identity to JQ750990 (103) and 92.4-99.6% to AF397905. The two GII.13 genotypes had a 
96.9% identity and a closer identity of 98.1-98.8% to AB447409 (109) than 93.2-94.8% for 
AY113106. 
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4.3.3  PATIENT DEMOGRAPHICS 
4.3.3.1  Norovirus Distribution 
Norovirus was found in all months of the two year study period. There were similar positives 
numbers in 2009 (48.6%) and 2010 (51.4%) with norovirus infection rates of 7.1% in 2009 
and 7.4% in 2010. In 2009, infection rates increased with the cooler months, to a peak in 
August and September. In 2010, infection was spread throughout the year and peaked in 
December (Figure 4.6). In 2009, 12 genotypes were detected with GII.4 2008 variant 
responsible for the majority of infection (45.2%), followed by GII.4 2006b variant (21.6%), 
GII.3 (18.2%), GII.4 2010 variant (6.8%) and GII.6 (3.4%).  The other seven genotypes 
detected were each responsible for 0.6% infection: GI.2, GI.4, GI (unknown subtype), GII.2, 
GII.7, GII.12, and GII.13. In 2010, 11 genotypes were detected with GII.4 2010 variant 
causing 44.2% infection. The other seven GII genotypes detected were: GII.3 (17.9%), GII.4 
2008 (14.7%), GII.7 (11.0%), GII.12 (4.2%), GII.4 2006b (3.7%), GII.2 (1.0%) and GII.13 
(0.5%). There were three GI genotypes in 2010, each responsible for 0.5% infection: GI.1, 
GI.6 and GI.13. 
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Figure 4.6  Seasonal distribution of norovirus genotypes from January 2009 to December 2010 
 
4.3.3.2  Patient Types 
In the patient type analysis of norovirus infection, 231 positive specimens (63.1%) were from 
patients presenting to the Emergency Department, 90 (24.6%) from immunocompromised 
patients presenting to the Outpatient Clinics and 45 (12.3%) from nosocomial acquired 
infection (Table 4.4).                                                                                                                  
In the Emergency Department patients, 169 (73.1%) were clinically diagnosed with 
gastroenteritis and 62 (26.9%) with diarrhoea or loose stools on presentation at the hospital. 
The six patients with norovirus GI infection were all from the Emergency Department (2.4% 
each). There were seven norovirus GII genotypes detected, with the majority of patients 
infected with GII.4 2008 variant, 66 patients (28.1%), and GII.4 2010 variant, 65 patients 
(27.7%). The other five norovirus GII genotypes responsible for infection were: GII.3 in 40 
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patients (17.0%), GII.4 2006b variant in 28 patients (11.9%), GII.7 in 12 patients (5.1%), 
GII.6 in 6 patients (2.6%), GII.12 in 3 patients (1.3%), GII.13 in 2 patients (0.85%) and one 
patient with GII.2 (0.45%). There were four cases of co-infection with bacteria: Salmonella 
spp. in 3 patients with GII.4 2010 variant, GII.7 and GII.12 genotypes, and one patient with 
Campylobacter sp. and genotype GII.3. There were six patients with GII.4 infections 
following recent overseas travel: two patients from Lebanon, three from India and the patient 
with GI.4/GII.4 infection had returned from London.                                                                                                                  
In the immunocompromised patients, 47.0% were clinically diagnosed with gastroenteritis 
and 53.0% with diarrhoea or loose stools on presentation to the Outpatient clinics. In these 
patients, there were no norovirus GI genotypes detected.  There were five norovirus GII 
genotypes detected with GII.4 the most common (60.0%): 26  patients with GII.4 2010 
variant (28.9%), 18 patients with GII.4 2008 variant (20.0%),  14 patients with GII.3 (15.6%), 
10 patients with GII.4 2006b variant (11.1%), 6 patients with GII.12  (6.7%) and 2 patients 
with GII.2 (2.2%). There were three cases of co-infection with astrovirus: two patients with 
HAstV-1d genotype, one patient with HAstV-1a genotype and one case of co-infection with 
rotavirus. None of the immunocompromised patients had a history of recent overseas travel.  
There were five immunosuppressed patients with long term norovirus infections involving 
genotypes GII.3 and GII.4: one patient with GII.3 genotype for 3 months, one patient with 
GII.4 2006b variant for 4 months, two patients with GII.4 2008 variant for 6-7 weeks and one 
patient with GII.4 2010 variant for 10 weeks.                                                                                               
There were seven outbeaks of nosocomial acquired infection over the two year study period: 
five in 2009 and two in 2010, both involving different hospital wards. Of the seven outbreaks, 
four involved GII.4 2008 variant genotype and the other three outbreaks were due to GII.4 
2006b variant, GII.4 2010 variant and GII.3 genotypes. The majority of nosocomial 
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infections were due to GII.4 2008 variant (46.7%), followed by GII.3 (24.4%), GII.4 20006b 
variant (13.3%), and GII.4 2010 variant (8.9%) genotypes. 
 
 4.3.3.3. Age Distribution 
The age of children with norovirus infection ranged from one month to 15 years and the 
median age was 2.17 years. Incidence of infection was higher in children under five years of 
age (8.6%).  The highest incidence was in the 1-2 year age group (10.9%) followed by the 6-
12 months age group (9.8%) (Figure 4.7A). The largest variety of norovirus genotypes was 
present in the 1-2 year age group (Figure 4.7B). Genotypes GII.3, GII.4 2006b variant, GII.4 
2008 variant and GII.4 2010 variant were found in all age groups. The genotypes responsible 
for the highest infection rates per age group were: GII.4 2010 variant for 0-6months (2.6%), 
GII.4 2008 variant for 6-12 months (2.9%) and 1-2 years (4.0%), GII.4 2010 variant for 3-5 
years (2.5%) and 6-10 years (1.5%), and GII.7 for the oldest 11-15 year age group (0.9%). 
Genotype GII.3 was responsible for similar infection rates to GII.4 2008 variant in the 6-12 
month (2.4%) and 1-2 year (2.3%) age groups. Low infection rates for the remaining four GII 
genotypes: GII.2, GII.6, GII.12 and GII.13 and GI genotypes made age distributions unclear. 
The ratio of infection in males was slightly higher than females at 7.7% (215 out of 2807) and 
6.9% (155 out of 2245), respectively. The GII.4 genotype was predominant in males with a 
ratio of infection of 5.3% compared to 4.2% in females. This was due to the lower ratio for 
GII.4 2006b variant in females (0.4%) compared to males (1.3%). As in the age group 
comparison, low infection rates for the other genotypes made male/female distributions 
unclear. 
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Figure 4.7  Percentage positive specimens for (A) norovirus per age group and (B) norovirus 
genotypes per age group                                                                                                                                                                  
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4.4  DISCUSSION 
In this two year study, over 5000 stool specimens from children presenting with diarrheal 
symptoms to the Emergency Department, Outpatient Departments and from inpatients at The 
Children’s Hospital at Westmead were tested for astrovirus and norovirus infection. The 
ELISA methods showed an incidence of 0.5% (24/5052) and 6.6% (331/5052) for astrovirus 
and norovirus, respectively. The astrovirus nRT-PCR assay detected all ELISA positive 
specimens and 7 out of 150 ELISA negative specimens. Thus, compared to the nRT-PCR 
assay, the astrovirus ELISA had a sensitivity and specificity of 77.4% (95% CI= 58.9-90.4%) 
and 100% (95%CI= 97.5-100.0%), respectively. On the other hand, the norovirus nRT-PCR 
assays detected nearly 98.8% of the  ELISA positive specimens and 23 in the 88 ELISA 
negative specimens, resulting in a sensitivity of 93.3% (95% CI= 90.2-95.7%) and specificity 
of 94.2% (95%CI= 85.8-98.4%) for the norovirus ELISA. The estimated incidences if all 
study specimens were tested by both ELISA and nRT-PCR were 5.1% (95% CI= 4.53-
5.77%) for astrovirus (260 of 5052specimens) and a high 30.9% (95% CI= 29.63-32.19%) for 
norovirus (1564 of 5052 specimens).                                                                                                     
Astrovirus genotypes, HAstV1 to 4, were detected with HAstV-1a the predominant genotype 
For norovirus, 12 genotypes were detected: NoV GI.1, GI.2, GI.4, GI.6, GI.13, GII.2, GII.3, 
GII.4, GII.6, GII.7, GII.12, GII.13 with NoV GII.4 the predominant genotype.  For both 
astrovirus and norovirus, infection rates were similar in 2009 and 2010 and the highest rates 
of infection were found in children under two years of age. Astrovirus infection was mainly 
found in Emergency patients and immunocompromised patients, with only one patient with 
nosocomial infection. In contrast, the majority of norovirus infection was found in 
Emergency patients and to a lesser extent in immunocompromised patients. Norovirus was 
responsible for more nosocomial acquired patient infections (12.3%).                                                                                                                             
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In summary, the ELISA tests as screening tests for astrovirus and norovirus antigens were 
rapid, specific and relatively easy to perform on our large number of study specimens. 
However, the developed nRT-PCR assays with increased sensitivity were able to detect 
astrovirus RNA in 5% of the ELISA negative specimens and norovirus RNA in 26% of the 
ELISA negative specimens and viral genotypes could be determined. Both testing 
methodologies could be employed by diagnostic laboratories but their advantages and 
disadvantages need to be considered and discussed in the next chapter. 
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5.1  DISCUSSION 
Since the introduction of rotavirus vaccines in 2005, there has been an estimated 49-89% 
reduction in rotavirus hospital admissions in countries that have included the vaccine in their 
national immunisation programs. In Australia, rotavirus vaccination was included  in the 
national immunization program from mid 2007 and by 2010 there was an 87% reduction 
(110). In this research project, we investigated the activities of astrovirus and norovirus in 
2009 and 2010 in children with diarrhoea at CHW to assess whether the infection incidence 
of these two viruses increased with the decrease in rotavirus activity. Results from the 
commercial astrovirus and norovirus ELISA tests and the in-house developed nRT-PCR 
assays were used to determine the prevalence and nature of astrovirus and norovirus 
infection. Comparison of the performance of the ELISA tests and nRT-PCR assays allowed 
us to determine the most suitable test for routine diagnostic use. 
Compared to the nRT-PCR assay, the astrovirus ELISA sensitivity was 77.4% (95% CI= 
58.9-90.4%) and specificity was 100% (95% CI= 97.5-100.0%). The sensitivity of the 
norovirus ELISA test compared to the nRT-PCR assays was 93.3% (95% CI= 90.2-95.7%) 
and specificity was 94.2% (95% CI= 85.8-98.4%). With both viruses, the performance of the 
nRT-PCR assays were necessary as the single round RT-PCR failed to detect all of the 
ELISA positive specimens and viral RNA in the ELISA negative specimens tested. Several 
astrovirus studies have also shown nRT-PCR to be more sensitive than single round RT-PCR 
for RNA detection, and the use of single round RT-PCR alone may underestimate the 
prevalence of astrovirus (86, 111). Likewise with norovirus, several studies have shown that 
it is difficult to detect norovirus with single primer sets and sensitivity of norovirus detection 
is increased by the use of nested RT-PCR or single-round RT-PCR with a combination of 
primer sets (112-114).    
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 There have not been many published studies comparing the performance of the 
RIDASCREEN
®
 Astrovirus ELISA test to RT-PCR. Apart from this study, there has been 
only one report from 2011 (115) that claimed a sensitivity and specificity of 100.0% when 
compared to real-time RT-PCR. However, this may have been an over-estimation as only two 
in 140 stool specimens were positive for astrovirus.                                                                       
One reason for the high sensitivity of the norovirus ELISA test in this study may be due to 
the occurrence of two large norovirus epidemics in the 2009 and 2010 winter seasons caused 
by the pandemic GII.4 variant known as New Orleans 2010. Sensitivity of the 
RIDASCREEN
®
 norovirus ELISA test has been shown to increase in outbreak situations 
where viral load is higher (116, 117) and some studies have shown this ELISA test to have a 
higher sensitivity to genotype GII.4 (117, 118). Recent studies have shown sensitivities and 
specificities ranging from 63.0-92.9% and 94.0-98.0%, respectively, when comparing the 
RIDASCREEN
®
 3
rd
 generation ELISA test to RT-PCR (Table 5.1). The large sensitivity 
variation may be due, again, to the periods when the study specimens were collected: the 
study with the lowest sensitivity of 63.0% from Kirby et al. (118) tested specimens from 
October 2006 to December, 2007, whilst the studies with higher sensitivities tested specimens 
during 2008 to 2010.  Taking these factors into consideration, our two year study may have 
overestimated the sensitivity of the norovirus ELISA test, and extension of our study by one 
or two years with varying levels of norovirus activity, may have provided a better estimation. 
The small variation in specificities could be due to a combination of different RT-PCR 
methodologies and primers targeting different areas of the viral genomes.                                                    
The estimated sensitivities and specificities of the ELISA methods compared to the nRT-PCR 
assays in this study may have improved if more negative ELISA specimens were tested by 
nRT-PCR. However, this was not possible due to financial constraints and time limitations 
for this project.  
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Table 5.1  Sensitivity and specificity of RIDASCREEN
®
  Norovirus 3
rd
 generation ELISA test to RT-
PCR in published studies                                                                                                                                              
*= 3PCR kits, 2 were commercial kits     rRT-PCR= real-time RT-PCR 
Region A: RdRp gene, ORF1 
Region B: 3’ end of ORF2 
Region C: ORF1/ORF2 junction 
 
The ELISA results showed an astrovirus incidence of 0.5% and norovirus incidence of 6.6%, 
however, incidences were estimated to be 5.1% (95% CI= 4.53-5.77%) and 30.9% (95% CI= 
29.63-32.19%), respectively, if all specimens were tested by both ELISA and nRT-PCR. 
Astrovirus incidences in published studies from 1995-2009 are shown in Table 5.2. In most 
countries, astrovirus incidence was from 1.5-7.0%, except for one study in Brazil (6) and 
another in China (86) where these studies were conducted in lower socio-economic regions 
within these countries where the incidence was higher. The 5.1% incidence in our study is 
slightly higher to that observed in previous Australian studies from 1995-1998 prior to 
Rotavirus vaccine introduction. There have been no recent Australian reports on astrovirus 
infection in paediatric patients to compare our result post rotavirus vaccine. However, our 
finding is similar to those reported in Brazil and the U.S., two countries with Rotavirus 
vaccine programs introduced in 2006.                                                                                                                                              
 
 
 
 
 
COUNTRY PCR 
METHOD 
SENS. 
(%) 
SPEC. 
(%) 
PRIMER REGION REFERENCE 
Australia nRT-PCR 93.3 94.2 Region C This study 
Brazil nRT-PCR 92.9 97.2 Regions A and B (119) 
Germany rRT-PCR 77.0 96.0 2 Region B,1 unknown* (120) 
Australia rRT-PCR 76.6 97.5 Region C (121) 
Brazil rRT-PCR 63.0 98.0 Region C (118) 
Brazil RT-PCR 78.3 94.0 Region B (122) 
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Table 5.2  Astrovirus incidence from 1982 -2009 in countries with and without rotavirus vaccination 
programs in published studies 
rRT-PCR= real-time RT-PCR 
 
Norovirus incidences reported from 1998-2011, including countries with rotavirus 
vaccination programs post 2005, are shown in Table 5.3. The estimated incidence in our 
study is within the range of 21.0-36.5% in publications since 2005. The other Australian 
study by Maher et al (128) post 2007 rotavirus vaccine introduction, showed a slightly higher 
norovirus incidence of 36.0%, compared to our finding of 30.9% after three years of rotavirus 
vaccination. The two countries with rotavirus vaccination programs introduced in 2006, the 
U.S. and Brazil, had a lowest incidence of 21.0% and one of the highest at 36.5%, 
respectively. Consistently observed in the studies in Brazil, the U.S. and Australia, norovirus 
incidence rates were lower prior to vaccine introduction at 14.5%, 11.9% and 8.7% 
respectively. A recent study in Finland (129), after two years of vaccination, has shown a 
slight increase in activity to 33.6% from 26.0% pre-vaccine. The increase in norovirus 
activity may be due to the reduction in rotavirus activity as a result of vaccine 
implementation post 2005. However, there has also been an increase in norovirus activity 
COUNTRY STUDY 
YEARS 
METHOD ASTROVIRUS  
INCIDENCE (%) 
VACCINE  
INTRODUCED 
REFERENCE 
Australia 2009-2010 nRT-PCR 5.1 2007 This study 
U.S. 2008-2009 rRT-PCR 4.9 2006 (123) 
Brazil 1994-2008 rRT-PCR 6.3 2006 (17) 
China 2005-2006 rRT-PCR 
+ nRT-PCR 
9.2 no (86) 
Italy 2002-2005 RT-PCR 4.0 no (8) 
France 2001-2004 RT-PCR 1.5 no (7) 
Germany 2001-2002 nRT-PCR 4.0 no (111) 
Brazil 1982-2000 RT-PCR 6.1 pre-vaccine (61) 
Spain 1997-2000 RT-PCR 4.9 pre-vaccine (124) 
Ireland 1996-1998 RT-PCR 7.0 no (125) 
Brazil 1994-1999 RT-PCR 28.2 pre-vaccine (6) 
Australia 1995 RT-PCR 4.2 pre-vaccine (126) 
Australia 1995-1998 RT-PCR 3.0 pre-vaccine (66) 
Australia 1995-1998 RT-PCR 4.3 pre-vaccine (15) 
Australia 1997-1998 RT-PCR 4.1 pre-vaccine (127) 
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since 2002 as a result of pandemics with NoV GII.4 variants which have occurred worldwide 
every two years: the Farmington Hills variant in 2002 (55), Hunter variant in 2004 (90), 
2006b variant in 2007 and 2008 (130) and the New Orleans variant in 2009 and 2010 (107, 
131). Studies before 2005 showed a wide incidence range, from a low of 8.7% to a high of 
35.0% and this may be explained if studies were conducted during norovirus pandemics.   
 
Table 5.3  Norovirus incidence from 1998 -2011 in countries with and without rotavirus vaccination 
programmes in published studies 
COUNTRY STUDY 
YEARS 
METHOD NOROVIRUS 
INCIDENCE (%) 
VACCINE 
INTRODUCED 
REFERENCE 
Australia 2009-2010 nRT-PCR 30.9 2007 This study 
Finland 2009-2011 RT-PCR 33.6 2009 (129) 
Brazil 2008-2010 RT-PCR 36.5 2006 (122) 
U.S. 2009-2010 rRT-PCR 21.0 2006          (132) 
U.S. 2008-2009 RT-PCR 21.4 2006 (123) 
Italy 2009-2010 rRT-PCR 15.7 no          (133) 
China 2007-2010 RT-PCR 25.9 no          (103) 
China 2008-2009 rRT-PCR 25.6 no (134) 
Hong Kong 2008 RT-PCR 23.0 no (135) 
Japan 2007-2009 nRT-PCR 26.6 no (114) 
Finland 2006-2008 RT-PCR 26.0    pre-vaccine  (11) 
Australia 2006-2008 nRT-PCR 36.0 mid-vaccine (128) 
Turkey 2006-2007 RT-PCR 17.1 no (136) 
Spain 2005-2008 RT-PCR 17.2 no (137) 
U.S. 2004-2005 rRT-PCR 11.9 pre-vaccine (138) 
Germany 2001-2002 nRT-PCR 35.0 no (111) 
Australia 1998-2002 RT-PCR 8.7 pre-vaccine (139) 
Brazil 1998-2005 rRT-PCR 
+ RT-PCR 
14.5 pre-vaccine (140) 
rRT-PCR= real-time RT-PCR 
In the present study, HAstV-1 was the most common genotype detected, being identified in 
nearly 80% of the astrovirus positive specimens. This was followed by HAstV-3 (10.7%) and 
HAstV-4 (7.1%), with HAstV-2 detected in only one specimen (3.6%). Amongst the HAstV-
1 positive specimens, around 60% were of lineage HAstV-1a and the rest of lineage HAstV-
1d.  This finding is different to previous Australian studies; only HAstV-1a and HAstV-1b 
had been detected in paediatric specimens (15, 66, 126). To our knowledge, HAstV-1d has 
been detected only in the elderly in Australia (44) but not in children. This may reflect the 
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fact that HAstV-1a and HAstV-1d have become the dominant lineages of astrovirus infection 
worldwide. Recently, HAstV-1a has been detected in Korea, Brazil, (16, 87) and HAstV1-d 
in China, Italy, and Vietnam (8, 86, 141). It is noteworthy that almost half of the astrovirus 
positive specimens were from immunocompromised patients. Astrovirus infection in these 
patients may be chronic, with the long-term shedding of virus as a source of nosocomial 
infection, and in some instances fatal in severely immunocompromised patients (142). In 
these patients, clinical symptoms were typically diarrhea or loose stools (75%) rather than 
acute gastroenteritis. Detection of astrovirus in these patients may be critical for their long-
term care.  
Genotype GII.4 was responsible for the majority on norovirus infections during the study 
(68.2%) with three epidemic GII.4 variants detected. In 2009, GII.4 2008 variant was 
responsible for the majority of infection (45.2%), followed by one of the 2006 pandemic 
strains GII.4 2006b variant (21.6%). In August, 2009 the pandemic GII.4 2010 New Orleans 
variant was detected and together with the other two variants was responsible for the late 
winter peak of infection and the highest norovirus activity during the study period. The GII.4 
2010 variant continued throughout 2009 and was responsible for the majority of infection in 
2010 (44.2%), replacing GII.4 2008 (14.7%) and GII.4 2006b (3.7%). This pattern of 
infection with the three GII.4 variants has been seen in Australia and other countries around 
the world (107, 143, 144).  The majority of norovirus infections were in the Emergency 
Department patients (75%) and immunosuppressed patients accounted for 24.6% of infection. 
However, there were a large number of nosocomial infections (12%).                                                                                    
It is difficult to assess the impact of rotavirus vaccine introduction on the activity of 
astrovirus and norovirus as many countries have not introduced the vaccine into their national 
immunisation programs. As more countries introduce the vaccine, further studies will be able 
to clarify this. According to the WHO Country National Immunization Program (NIP), by 
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early 2013 only 45 countries (23%) had introduced Rotavirus vaccine in their national 
immunization program since vaccines were licensed in 2005 (145). Interestingly, the 
countries that have not commenced national rotavirus vaccinations include most of Europe, 
the U.K., China, Russia Canada, India, Malaysia and Indonesia where many of the past 
astrovirus and norovirus studies have been performed. The U.K and India plan to start the 
implementation of national rotavirus vaccination by the end of 2013.                 
 
  5.2  CONCLUSION 
The astrovirus and norovirus ELISA tests and nRT-PCR assays, two very different 
methodologies, were used to test stool specimens in our study. The ELISA tests detect viral 
antigens, whilst the nRT-PCR assays detect viral RNA in stool specimens. Whilst ELISA 
tests are quick and easy to perform, they are less sensitive compared to molecular methods. 
Molecular methods, on the other hand, are more expensive, have a longer turnaround time 
and require more technical expertise than ELISA. Performance of PCR assays can also vary 
as primers can be directed to different regions of the viral genomes in PCR.  Likewise, 
performance of ELISA tests can vary depending on the monoclonal antibodies used in the 
detection system.                                                                                                                    
This study was performed from a diagnostic laboratory point of view and interpretation of 
results are from this perspective. The norovirus ELISA test with its high sensitivity was a 
rapid, easy to perform and relatively inexpensive method to screen the large numbers of 
specimens in this study. Taking this into consideration, together with the high incidence of 
norovirus found in this study, the ELISA test would provide rapid results for Emergency 
patients and would aid in patient management during nosocomial outbreaks. The increased 
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sensitivity of the nRT-PCR assays could be utilized where norovirus diagnosis is critical to 
patient care, as with immunocompromised patients, or in non-pandemic periods when lower 
viral loads may reduce the sensitivity of the ELISA method. The astrovirus ELISA sensitivity 
was not as high as the norovirus ELISA, and considering the low astrovirus incidence over 
the study period, the nRT-PCR assay would be more suitable for testing patient specimens. 
Rather than the astrovirus nRT-PCR being performed as a routine diagnostic test on all stool 
specimens, it may best be used to test specimens from patients where astrovirus detection is 
critical, such as in immunosuppressed patients.                                                                                 
In conclusion, our study results showed that astrovirus is an uncommon cause and norovirus a 
common cause of diarrheal illness in children presenting to The Children’s Hospital at 
Westmead. The activity of astrovirus does not seem to have been effected by the introduction 
of rotavirus vaccine as its incidence has remained low, however, the activity of norovirus has 
been more variable and has increased as a result of worldwide pandemics.  The effect of 
rotavirus vaccination on the activities of both viruses will require further studies, both in 
Australia and worldwide, as more countries include the vaccine in their national 
immunization programs. 
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